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Acute Methamphetamine Exposure Effects Histone Modifying Enzymes and
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Ariel Burns, Candidate for the Doctor of Philosophy Degree
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ABSTRACT
The effects of methamphetamine (Meth) in the periphery are not well studied and a
comprehensive investigation on the effects and molecular mechanism will give insight
into why Meth users are at an increased risk of infections. For this reason, we use
macrophages as a model for the immune system dysregulation seen in Meth abusers
and also because macrophages are a long-lived cell that HIV infects and persists in. We
aimed to determine the effects of Meth on the cytokine production, histone modifying
enzymes and the corresponding histone post-translational modifications, and the
molecular mechanism in HIV-infected human macrophages treated with combination
antiretroviral therapy.
We measured a total of six histone deacetylases (HDACs) and found that Meth
decreases HDAC1 but not in HIV or HIV and Meth. Combinational antiretroviral therapy
also did not seem to have an effect on any HDACs measured. The decrease in HDAC1
correlated to an increase in acetylation of HDAC1 histone targets, histone 4 lysine 5 and
histone 3 lysine 18. Next, we determined that Meth induces a time-dependent and
concentration dependent change in cytokine expression. Furthermore, Meth generated a
rapid induction of pro-inflammatory cytokines at two hours and maintained until 6 hours
post exposure. Subsequently, we expanded on where Meth could be affecting the TLR9
signaling pathway to support the result of altered cytokine production by looking at DNA
methylation, presence of transcription factors, and TLR9-mediated signaling mediators.
In conclusion, Meth decreases HDAC1, modifies cytokine production in macrophages
leading to a pro-inflammatory phenotype.
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General Introduction
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1.1.

Brief History of Meth
Methamphetamine hydrochloride (Meth), or crystal meth, was synthesized by a

Japanese pharmacologist, Akira Ogata, in 1919 via reduction of ephedrine using red
phosphorus and iodine [1]. Throughout the years, it was manufactured in pill form by
pharmaceutical companies all over the world and had many names: Philopon (Japan),
Pervitin (Germany), Obetrol (United States), and is still manufactured and prescribed as
Desoxyn (United States) [2]. It has been prescribed for asthma and narcolepsy, and
used as an alertness aid and an appetite suppressant to regulate weight [3]. The use of
Meth skyrocketed during World War II when both the German and Japanese soldiers
used it to enhance their performance and to prevent depression on the frontlines. The
Japanese Kamikaze pilots also reportedly used it before suicide missions [4]. It was not
until the 1960’s that the abuse worsened when doctors in California began administering
an injectable form of Meth to treat heroin addicts [5]. Eventually, as the addictive
qualities of the drug became apparent, governments began to regulate the production
and distribution of prescription Meth more strictly. The United States made Meth a
schedule II controlled substance under the Controlled Substances Act in 1970. Soon
after the illicit underground the market for Meth grew, manufacturing of Meth starting in
California and eventually moving eastward. In the Midwest rural areas Meth labs
became popular because of the ease and accessibility of anhydrous ammonia tanks, an
ingredient to needed to produce Meth.
During the 1990’s and the early 2000’s, as illicit Meth manufacturing and abuse
became endemic throughout the states, Meth research rose exponentially. Studies found
it to be very dangerous and highly addictive compound, associated with permanent brain
damage in long-term users [8, 9]. Furthermore, Meth use is correlated with an increase
in mortality, as well as a dramatic rise in the violent crimes [10]. In addition, studies
15

found a positive correlation of Meth use with lowered sexual inhibitions and poor
judgment, possibly contributing to the spread in transmission of Human Immunodefiency
Virus type 1 (HIV-1) [11-13]. Due to the devastating effects of Meth on individuals and in
the communities, Congress passed the Comprehensive Meth Control Act in 1996. This
law regulated mail order and chemical companies selling precursor chemicals, such as
red phosphorous, iodine and hydrochloric gas and required that companies show a
legitimate use for the chemicals. The law also limited the quantity of the over-the-counter
cold medications containing pseudoephedrine, another precursor chemical, and for the
sale of these medications be a documented transaction. In conclusion, Meth is a very
popular (over an estimated 1.4 million people used within the last year in the United
States) and has become the drug of choice over other illicit psychostimultant drugs,
including cocaine, heroin, and crack since Meth is cheaper and has longer lasting effects
[14].

1.2.

Chemistry of Meth
The chemical formula of Meth is C10H15N and its molecular weight 149.23 g/mol.

It structurally similar to other abused drugs like amphetamine, ephedrine, and MDMA
(ecstasy), as well as monoamine neurotransmitters like dopamine, epinephrine, and
norepinephrine (Fig. 1.1.). Pharmacokinetic properties help explain how the body
responds after Meth is administered and are measured by bioavailability (how easily the
body absorbs a drug), volume of distribution (where in the body the drug will be located),
and the half-life (how quickly half the dose is eliminated). Bioavailability, by definition, is
the percentage of an administered non-metabolized drug that reaches the systemic
system and therefore, 100% of a drug reaches the blood stream for intravenous doses.
But when a drug is given orally the drug is metabolized or not absorbed thus decreasing
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Figure 1.1. Similarities of chemical structures to methamphetamine

The bioavailability. Meth has a high bioavailability regardless of ingestion route whether
smoked (90.3%) or swallowed (67.2%) [15]. The volume of distribution (Vd) is a
measurement of how much of the dose is in the tissues versus retained in the plasma.
Drugs with low plasma binding capabilities have higher Vd and Meth has a moderate Vd
of 5.8 L/kg for a 10 mg oral dose [16]. There are no known proteins that bind Meth in the
plasma.The secondary amine group on Meth makes it more lipophilic, suggesting why
Meth is distributed in tissues, including the brain, rather than the blood [17]. The last
important property is half-life. The half-life is the amount of time it takes for the
concentration of drug in blood plasma to reach one-half the original amount. The plasma
half-life for Meth is an average of 12 h, significantly longer than cocaine which has halflife of 90 min [15, 18]. Taken together these properties show that Meth is easily
distributed throughout the body tissues and is retained for long periods of time [18-20].
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1.2.

Cellular Mechanism of Meth Addiction
Meth affects the regions of the central nervous system (CNS) that control

judgment, reward-seeking behavior, and memory. Meth activates the prefrontal cortex,
amygdala, and the nucleus accumbens [21, 22]. The prefrontal cortex is responsible for
making decisions and cognition and innervates to the amygdala that is associated with
emotional control and memory formation [22]. The nucleus accumbens processes the
understanding of pleasure, reward, and reinforcing behaviors [23]. To this extent, these
brain regions help elucidate the behavioral changes seen in Meth users like decreased
inhibition, grandiosity, increased libido and ease of becoming addicted to the feeling of
well-being.

Figure 1.2. Dopamine Released as a Result of Natural Stimuli (Source: Di Chiara et
al.) [24]
The main cell type in the brain regions that affect Meth and addiction is
dependent on dopaminergic neurons. Due the neurotoxicity of Meth, and a loss of

18

Figure 1.3. Dopamine Levels Released After Addictive Drugs Over Time (Source: Di
Chiara et al.) [24]

dopaminergic neurons, chronic users develop a tolerance to Meth. The increased
tolerance makes users actively seek out higher doses (drug-seeking behavior), increase
frequency of ingestion. The exact mechanism or mechanisms causing neurotoxicity from
Meth is not known but many have been proposed, including inflammation, reactive
oxygen species disrupting mitochondria function, disruption of the blood brain barrier,
free radicals causing DNA damage, and/or glutamate toxicity [25-28]. Dopaminergic
neurons are the main source of dopamine. Dopamine is a neurotransmitter released as
a result of rewarding experiences such as food, sex, and natural stimuli (Fig. 1.2.). Meth
releases magnitudes more dopamine than natural stimuli or other drugs making it very
pleasurable and those feelings desired to be repeated by users and abusers [24] (Fig
1.3.). Dopamine is a member of the catecholamine family and readily degraded in
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neurons by enzymes such as monoamine oxidase and catechol-O-methyl transferase.
Dopamine is naturally stored in vesicles until a stimulus induces its release. When Meth
crosses the blood brain barrier and the cell membrane of neurons, it replaces the
dopamine inside the vesicles [29]. Once dopamine is displaced, there is a higher
concentration gradient inside the cytosol than outside the cell triggering an efflux of
dopamine into the synaptic clefts [30]. Dopamine activating receptors on the postsynapse in the brain regions mentioned previously propagates the chemical
transmission and gives the effect of euphoria after Meth. The other cellular mechanism
giving rise to the euphoria effect is the prolonged duration of dopamine in the clefts.
Meth accomplishes this by inhibiting the reuptake of dopamine from the clefts by
blocking the extracellular dopamine transporter on the exon terminals of the presynaptic
neurons [31, 32]. Therefore, Meth is so addictive because it causes a large quantal
release of dopamine for sustained periods of time.

1.4.

Health and Social Impact of Meth
The physical effects of Meth are similar whether the drug is snorted, smoked,

injected, or swallowed. The short term effects of Meth are due to the activation of
sympathetic nervous system and are therefore, similar to the fight-or-fight responses,
including increased wakefulness, decreased appetite, increased breathing, heart rate,
and blood pressure [33]. Due to the lipophilic nature of Meth, Meth can pass through the
placenta to the fetus and cause premature delivery, separation of the placenta from the
uterus, low birth weight, and heart and brain problems in the child [34]. Long term effects
of chronic Meth use include weight loss, kidney failure, brain damage, depression,
hallucinations, permanent psychological problems, persistent ticks, violent and
aggressive behavior, “meth mouth” or dental disease and teeth rot, insomnia, behavior
resembling paranoid schizophrenia, increased susceptibility to infections, liver damage,
20

and stroke (because of increases in blood pressure, heart rate, and body temperature)
[8, 35, 36]. Chronic use can damage the cardiovascular system, lungs, liver, and
muscles [37-39]. Psychological addiction or dependence is when the user gets high to
avoid the negative effects or withdraw symptoms of Meth include such symptoms as
cravings, depression, irritability, shaking, and a loss of energy.
Clearly, Meth has many short term and long term physical and psychological
effects on the individual user but there are societal concerns and policies being set
against the illegal use of Meth that have a huge monetary price. The social problems
associated with Meth addiction come from crime and incarcerations, death, treatment
facilities, and educational programs. In the most recent RAND study, the total economic
cost of Meth is estimated at an average $23.4 billion [40]. Each estimate discussed will
go further into detail of the actual break down included in the amount but will always
have intangible cost and therefore, should be considered as a conservative estimate.
Here, only the average cost will be reported, whereas the lower and upper limits are
outlined in the study.
In order to pay for their habit, addicts are tempted to rob, steal, or burglarize. This
type of crime is just one category grouped under property damage and violent crimes.
Another example of violent crimes committed by Meth abusers is physical violence. As
mentioned previously, Meth use can lead to irritability, violent and aggressive behavior
and according to one study Meth users reported violence against their partner, friends,
family, or strangers at least once [41]. The other categories are arrests for Meth
possession or sales and parole or probation revocation. More details contributing to the
cost are the length of the prison sentence and cost associated per day per person and
cost of drug testing of parolees. The best estimate for all of these expenses is $4.2
billion, noticeably a huge portion of total economic cost of $23.4 billion.
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A Meth related death is defined by the World Health Organization as a death
caused by mental or behavioral disorders due to psychoactive substance use or
poisoning of accidental, intentional, or undetermined intent. It is not just death but also
injuries caused by Meth lab mishaps, chemical fires, and or hospitalization from
inhalation of toxins from the ingredients of manufacturing Meth. Also, when explosions
happen in the Meth labs there is a societal cost accompanying professionals to cleanup,
process, properly dispose of chemical and hazardous waste. The cost of deaths was an
average of $31.5 million and injuries added an additional $1 million while, the cost of
cleaning up labs was $29.2 million. Yet, these estimates do not include the cost of
pollution caused by the dumping, burying, or burning of the hazardous waste
manufactured by each pound of Meth. Nor does the estimate include the cost of
decontamination of individuals on the Meth lab sites or evacuation of nearby neighbors.
Methamphetamine is a highly addictive drug and requires intense, long-term
treatment. Treatment cost in the United States can be split between the community
based treatment facilities (hospitals and specialty) and the federally provided treatment
programs, which include Department of Defense, Veterans Affairs, Federal Bureau of
Prisons, and IHS. The cost breakdown is $506 and $545 million for community based
and federally provided treatment facilities, respectively [40]. According to the Alcohol and
Drug Services Study, the average daily cost of inpatient treatment (community based
facility) was about $76.13 per day in 2002, and the cost of outpatient treatment was
about $26.72 per day [42]. Most private Meth rehab centers offer financing options for
qualified patients or cost might be covered by insurance companies. Although,
uncompensated treatment can place a huge burden on the national budget in the range
of hundreds of millions of dollars [43].
Education campaigns against the use of Meth significantly raises awareness of
consequences and effects, influence users to use less Meth, and practice safe sex more
22

often in order to prevent sexually transmitted diseases [44]. And although, these
marketing campaigns are less expensive and more cost-effective for raising awareness
on important health and psychosocial issues than the cost associated with other
methods, it is still costly to the public and government associations, between $20 million
for one state and upper bounds of $448 million for the nation [40, 45].

1.5.

Effects of Meth on Innate Immunity
Interestingly, Meth addicts are more susceptible to infections, including, HIV-1,

Methicillin-resistant staphylococcus aureus (MRSA), genital herpes, fungal infections,
and bacterial meningitis [46-50]. Infections are fought by the innate immune system,
which is the rapid but non-specific first response to foreign pathogens and injuries in the
body. There are many cell types that facilitate the innate immune response, among them
macrophages are important because they are long-lived cells, harbor cryptoccal
neoformans, facilitate fungal dissemination, and are an HIV reservoir [51]. Macrophages
possess many functions to accomplish its role in both innate and adaptive immunity. In
innate immunity, macrophages act as scavengers or surveyors of the surrounding tissue
and rid the body of dead or dying cells and foreign particles by phagocytosis. In addition,
macrophages have a critical role in initiating and regulating inflammation. Macrophages
secrete cytokines and chemokines as a chemical signal to recruit other immune cells to
the site of infection. Macrophages are the foremost cell type that process and present
antigens, which plays a crucial role in initiating the adaptive immune response, or
production of antibodies. After digesting a pathogen, a macrophage will present a part of
the antigen to a corresponding T cell.
Studies have demonstrated that Meth alters many functions of macrophages.
Research on the effects of Meth on macrophage functions and their molecular
mechanisms can help elucidate why Meth users are at an increased risk to infections,
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hopefully leading to the development of immune boosting treatments that can offset the
deleterious effects. Various studies show Meth alone alters cytokine production. For
example, TNF-α, IL-8, IL-1β, MIP-1α (CCL3), MIP-1β (CCL4), IFN-α and other cytokines
in monocyte-derived macrophages (MDM), THP-1 macrophages, and dendritic cells
(another immune phagocyte) [50, 52-54]. It is not just cytokines that are altered but other
small chemical signals are found to be decreased like nitric oxide and superoxide [46,
55]. Another study showed that Meth reduces the ability of macrophages to rid the body
of tumor cells compared to the stimulation of gram negative bacteria (LPS) and double
stranded RNA viruses (poly I:C). Meth also decreased the expression of CD14, the coreceptor for TLR4, which detects LPS. [55]. Moreover, Meth treatment decreases the
ability of macrophages to clear HIV and worsens viral load in infected cells [56]. The
mechanism of increased viral load was attributed to the down-regulation of anti-viral
cytokine, IFN-α, and the increased expression of the HIV entry co-receptor, CCR5 in
primary human MDM [50]. Lastly, Meth prevents the phagocytosis of Candida albicans
and Cryptococcus neoformans, two major AIDS-related fungus pathogens [56, 57]. In
conclusion, Meth is immunosuppressive by decreasing the ability of macrophages to
respond normally to viruses, bacteria, and fungal infections.

1.6.

Effects of Meth on TLR Signaling
Since the discovery of the first mammalian toll-like receptor (TLR) in 1997, 11

have now been identified in humans. Functional analysis of TLRs revealed that they
recognize specific patterns or PAMPs (pathogen-associated molecular patterns) of
microbial components and the homodimers or heterodimers of the receptors then
activate specific signaling mechanisms. Although different TLRs recognize different
PAMPs, a majority of the signaling pathways converge to a common factor, MyD88
(myeloid differentiation factor 88) (Fig. 1.4.).
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Figure 1.4. Mechanisms of Toll-like Receptors

MyD88 contains a TIR (Toll/IL-1 receptor) domain in the C-terminal portion and a death
domain at the N-terminal portion. The C-terminal domain of MyD88 associates with an
activated TLR (referred to as TIRAP or TIR domain containing adaptor protein) while the
death domain at the N-terminal of MyD88 recruits the linker protein IRAK (IL-1 receptorassociated kinases) 1, 2 and 4. IRAK4 phosphorylates IRAK1, which in turn binds the
TRAF (tumor-necrosis factor-receptor associated factor) domain of TRAF6 to IRAK1 and
activates TRAF6. Ubiquitinated TRAF6 serves as a scaffold protein with TAK1 (TGF-β
activated kinase 1) and TAB2 (TAK1- binding protein 2). TAK1 then couples to the IKK
(inhibitor of NF-κB kinase) complex, which includes the scaffold protein NEMO (NF-κB
essential modulator). Once TAK1 phosphorylates IKK, IKK phosphorylates the IκBα
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protein (inhibitor of NF-κB alpha) and results in the dissociation of IκBα from NF-κB
allowing NF-κB to translocate to the nucleus and mediate an increase in inflammatory
cytokine genes such as TNF-α, IL-1 and IL-12 [58-61].
The effects of Meth on macrophage function, especially altered cytokine
production and decreased defense against bacterial and viral infections, have been
implicated to be a consequence of deregulated TLR signaling. One such study showed
that activation of TLR9 by its agonist CpG ODN up-regulates the expression of TLR9,
IFN-α, IRF-7, and MyD88. These anti-viral factors boost the immune response and
reduce the HIV viral load in macrophages in vitro. However, METH treatment of
macrophages greatly inhibited the anti-HIV effect mediated by TLR9 signaling by
inhibiting the expression of TLR9 and downstream signaling factors [62]. Upon activation
of TLR4 with LPS, that Meth exacerbated the TNF-α mRNA expression and protein
levels however, in conjunction with an IKK inhibitor TNF-α levels decreased suggesting
the common pathway of MyD88-dependent signaling in Meth-induced effects [63]. Taken
together, further studies need to be conducted to determine the molecular mechanism of
Meth in macrophages.
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Chapter 2

Effects of Meth on Macrophage Function and Signaling
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2.1.

Introduction

2.1.1. Toll-like receptor signaling in macrophages
Macrophages are key elements of the innate immune system that rapidly respond to
various stimuli such as bacterial, viral, fungal or parasitic infections, tissue injury as well as other
insults. Macrophages detect viral and bacterial infections by utilizing Toll-like Receptors (TLRs).
TLRs 1, 2, and 4 are expressed on the cell surface and detect bacterial components like
lipopolysaccharide (LPS), whereas intracellular TLRs 3, and 7-9 sense viral RNA and DNA. TLR
signaling consists of two pathways, the MyD88-dependent and MyD88-independent pathways.
The MyD88-independent pathway leads to the activation of IRF3 (interferon regulatory factors
3) and IRF7 to induce Type I interferons. In the MyD88-dependent TLR signaling pathway,
MyD88 (myeloid differentiation primary response gene 88) recruits IRAK4 (IL-1 receptorassociated kinase 4) and activates IRAK1. Activated IRAK1 interacts with TRAF6 (TNF-receptor
associated factor 6) to activate TGF-β–activated kinase 1 (TAK1). The TAK1-TRAF6 complex
simultaneously phosphorylates and polyubiquitinates IKK (I kappa B kinase). Post-translational
modifications of IKK relieve inhibition of NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells) and allow NF-κB to translocate to the nucleus and regulate the production of
pro-inflammatory cytokines and chemokines [1]. If TLR signaling is impaired, the host becomes
susceptible to an invading microorganism by failing to recruit other immune cells and not
eliciting the proper adaptive immune response.
2.1.2. Epidemiology of Meth and opportunistic infections
Methamphetamine (Meth) is one of the most addictive and destructive illicit drugs and
its use is on the rise [2]. Epidemiology data demonstrates that chronic Meth users are at an
increased risk of acquiring infections such as Methicillin Resistant Staphylococcus aureus (MRSA)
and HIV-1 [3-5]. Moreover, in vivo and in vitro studies show histoplasmosis, cryptococcal
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neoformans, HIV-1, as well as other sexually transmitted infections, tend to progress more
rapidly with the use of Meth [6-11]. This suggests that Meth has the ability to profoundly
interfere with the cell-mediated immune response. However there remains a lack of
understanding as to how Meth impairs immune cell function at the molecular level.
2.1.3. Delineating the mechanism of Meth-exposed macrophages
It has been shown in macrophages that Meth exacerbates LPS-mediated expression of
IL-8, TNF-α and IL-1β mediated by p38 MAPK and PI3-AKT signaling pathways [12]. Other
studies show that phagocytosis, antigen processing, and antigen presenting in macrophages is
diminished by Meth exposure [13]. These studies indicate that Meth exposure impairs
macrophage functions; however the exact mechanism is unknown. Several possibilities include
alterations in signaling mediators, transcriptional factors, histone

post-translational

modifications and DNA methylation [13, 14]. In this study, we investigated how exposure to
Meth affects macrophage cytokine production and subsequent observations of the impairment
of cytokine responses due to TLR9 signaling by recognition of DNA.

2.2.

Materials and Methods

2.2.1. Cell culture and treatments
THP-1 monocytes, a human monocytic cell line derived from an acute monocytic
leukemia patient, were obtained from ATCC (Manassas, VA), and plated at a concentration of
106 cells per mL. They were differentiated into macrophages in the presence of 200 nM phorbol
12-myristate 13-acetate (PMA, Sigma-Aldrich; St. Louis, MO) in complete media, which consisted
of RPMI-1640 medium (HyClone; Logan, UT) supplemented with 10% fetal bovine serum
(Atlanta Biologicals; Norcross, GA) and 50 µM of beta-mercaptoethanol (Gibco; Grand Island,
NY). All of the media was exchanged every other day for four days and cells were allowed to rest
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in complete media without PMA for an additional two days, at which point cells assumed a
macrophage-like phenotype (Fig. 2.1). On day six, media was either replaced with 100 µM
methamphetamine (Sigma-Aldrich) in complete media or control media for the specified times.
In a separate series of experiments macrophages were treated with either 1µg/mL of mock CpG
oligodeoxynucleotides 2243 (CpG ODN) or TLR9-stimulatory CpG ODN 2216 (both from
Invivogen; San Diego, CA) for specified times.
2.2.2. Cell viability assay
Both time-dependent and concentration-dependent experiments on the viability of THP1 macrophages were performed according to the MTT assay protocol. Macrophages were
seeded onto 96-well plates at a density of 5 × 104 cells/well and treated with 0, 1, 10, 100, 500,
and 1000 µM methamphetamine for two hours. In parallel experiments cells were seeded at the
same density and propagated for 2, 6, 24, and 48 hours of 100 µM Meth along with the
appropriate time control (RPMI media). Positive and negative controls consisted of 100% killed
macrophages or wells with only MTT reagent, respectively. The positive control macrophages
were treated with 1% Triton X-100 (Fisher Scientific; Fair Lawn, NJ) to permeabilize the cell
membrane. The cell viability was assessed using the MTT assay (Life Technologies; Carlsbad, CA).
Absorbance at 490 nm was quantitated using a SpectraMax M3 microplate reader (Molecular
Devices, Sunnyvale; CA, USA). Eight parallel replicates were measured for each condition.
2.2.3. Human cytokines and chemokines RNA PCR array
Total RNA was extracted using Trizol (Life Technologies) and cleaned using the RNeasy
Mini Kit according to manufacturer’s protocol (Qiagen; Germantown, MD). Only RNA that had a
260/280 ratio greater than 1.8 and a RIN value greater than 7 was used for reverse transcription
(RT) to synthesize cDNA using the RT2 First Strand Kit (SABioscience; Frederick, MD). Reverse
transcription and PCR was executed by following the SABioscience’s protocol with a total of 5 µg
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of RNA being reverse transcribed and DNA contamination eliminated by incubating with
genomic DNA elimination mix supplied by the manufacturer. RNA was converted to cDNA using
the RT Cocktail mixed with the DNA-free samples and incubated at 42ºC for 15 min followed by
heating at 95ºC for 5 minutes. Samples were diluted with the 2X RT2 SYBR Green Mastermix
before performing PCR on the Applied Biosystems StepOnePlus Real-Time PCR System using the
default settings. Every sample was loaded in triplicate by the fully automated Corbett Robotics
(San Francisco, CA) to provide uniformity across all plates. Relative abundance was calculated
using the comparative CT method [16].
2.2.4. RNA extraction and quantitative PCR
Cells were lysed directly in the culture dish with Trizol Reagent (Life Technologies). RNA
was resuspended in 10 mM Tris (Pro-Pure, Solon, OH) and 1 mM EDTA (Fisher Scientific), pH 8.0
in RNase free water. One microgram of RNA was converted to cDNA using the High Capacity
cDNA Reverse Transcription Kit (Life Technologies) per the manufacturer’s protocol. The primers
used to detect IL-8, TNF-α, CCL7, CXCL1, IFN-α, and TLR9 were purchased from Integrated DNA
Technologies (Coralville, IA); human GAPDH primers were obtained from Applied Biosystems
(Warrington, UK). The relative abundance of each gene was calculated using the comparative CT
method [15].
2.2.5. Harvest and protein extraction
THP-1 macrophages were washed thrice with phosphate-buffered saline (PBS, HyClone),
and collected for either protein or RNA. To obtain protein from whole cell lysates, cells were
scraped in PBS and pelleted by centrifugation at 1000 x g for 5 min at 4°C and re-suspended in
300 µL per 106 cells of lysis buffer. Lysis buffer contained 2% (w/v) SDS (Bio-Rad; Hercules, CA),
in 0.1 M Tris-HCl (Fisher Scientific), 0.1 M DTT (Promega; Madison, WI) and 1X Protease Inhibitor
Cocktail (Sigma-Aldrich). Cells were heated at 95°C for 5 min, allowed to cool, and 100 units/mL
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Benzonase Nuclease (Merck KGaA; Darmstadt, Germany) were added. Protein was quantified
using Pierce 660 Assay as per the manufacturer’s protocol using 50 mM ionic detergent
compatible reagent (Thermo Scientific; Rockford, IL). Twenty micrograms of whole cell lysate
from each condition were loaded onto a 4-12% bis-tris gel (Life Technologies) and separated at
100 V for 90 min and transferred to a PVDF membrane at 25 V for 90 min. Membranes were
blotted with antibodies recognizing the following antigens: NF-κB/p65 [Cat# 8242] (New England
Biolabs, Ipswich, MA), TLR9 [Cat# ab85860] (Abcam, Cambridge, United Kingdom), and IRAK1
[Cat# ab238] (Abcam) all at 1:1000 concentration overnight in 4°C.
2.2.6. Immunocytochemistry
THP-1 cells were plated and differentiated as described above. Methamphetamine and
CpG ODN treatment was for 2 hours on day 6 post-plating. Macrophages were washed three
times with PBS (HyClone), scraped, pelleted and resuspended in PBS to obtain a final
concentration of 1x105 cells per ml for cytospin. After cells were spun at 1000 rpm for 10 min on
glass microscope slides, cells were fixed to the slide with 4% paraformaldehyde (Sigma-Aldrich)
at room temperature for 30 min and rinsed once with PBS. Cells were blocked and
permeabilized simultaneously by using 0.5% Tween 20 (Fisher Scientific) in PBS (PBST)
supplemented with 10% normal goat serum (Invitrogen; Carlsbad, CA) for one hour at room
temperature and rinsed once with PBST. Slides were stained with TLR9 [Cat# Ab85860] (Abcam)
at 1:500 for 1 hour and rinsed three times with PBST for 5 min each before secondary antibody
was added at a concentration of 1:500 for 45 min at room temperature in the dark. Slides were
washed three times in PBST to remove secondary antibody and incubated with 1 µg/mL of DAPI
(Invitrogen) for 5 min. After one wash, one drop of Prolong Gold (Invitrogen) was added and a
cover slip was placed over cells prior to being visualized using Zeizz Axio Observer inverted
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microscope at 40X oil immersion and capturing images using AxioVision Release software
version 4.8.
2.2.7. Methylation pyrosequencing
DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen) according to
manufacturer’s protocol. Samples were treated with mock CpG, Meth, or Meth and CpG as
previously mentioned in Cell Culture and Treatments. Bisulfite treatment was carried out using
1000 ng of sample genomic DNA and the EZ DNA Methylation-Direct kit (Zymo Research,
Orange, CA). This process deaminates unmethylated cytosine residues to uracil leaving
methylated cytosine residues unchanged. To perform PCR reactions, 42 ng of bisulfite-modified
DNA was used as template. The PCR reactions were performed in a total volume of 50 µl for 35
cycles using Roche Diagnostic Corporation (Indianapolis, IN) FastStart Taq DNA Polymerase
(1.0U), MgCl2 solution (3.5 mM), dNTP’s (0.2 mM), sense primer (0.24 µM), antisense primer
(0.18 µM), with denaturation at 95 ºC for 30 seconds, annealing temperature for 45 seconds at
annealing temperatures specific to the primer and extension at 72 ºC for 1 minute (Table 2.1).
For a positive (high methylation level) control, Roche Diagnostic Corporation (Indianapolis, IN)
human lymphocyte genomic DNA was methylated using M. SssI (CpG) methylase kit (New
England Biolabs, Ipswich, MA). Methylated DNA (1000 ng) was treated with sodium bisulfite as
described above. Sodium bisulfite treated Roche human lymphocyte genomic DNA (1000 ng)
served as a negative (low methylation level) control. All PCR products were electrophoresed on
0.8% agarose gel, stained with ethidium bromide, and visualized for appropriate and pure
product before proceeding with all analyses using a Bio-Rad Laboratories (Hercules, CA) Gel-Doc
UV illuminator. Methylation percentage of each CpG was determined using a Qiagen (Valencia,
CA) Pyromark Q96 pyrosequencer and sequencing primer according to manufacturer’s
recommendations (Table 2.2.).
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2.3.

Results

2.3.1. Meth exposure affects the mRNA expression profile of cytokines and
chemokines
Macrophages were exposed to 100 μM Meth for 2, 6, or 24 h and profiled for a broad set
of 84 immune mediators including cytokines, chemokines, interleukins and growth factors. An
RT kit was optimized for the downstream real-time PCR-based gene expression analysis with the
Human Cytokine and Chemokine RT² Profiler PCR Arrays (SABiosciences), which is a 96-well
plate format that includes 84 immune mediators and the appropriate controls. The mRNA
expression profile resulted in identification of 58 differentially expressed mediators with more
than two-fold up or down regulation in at least one time point (Table 2.3). Meth elicited a strong
(more than 10-fold) up-regulation of CXCL16 and CXCL2, a moderate (5- to 10-fold) upregulation of IL-7, CCL20, CXCL1, CCL24, and IL-8, and a strong (more than 10-fold) downregulation of CCL7 (also called monocyte-specific chemokine 3 (MCP-3) at the 2 h time point.
TNF-α maintained moderate transcript levels at 2 and 6 h of Meth exposure. In addition, IL-10
became highly up-regulated at 6 h. Similarly, CXCL13 was up-regulated between 6 h and 24 h.
Some cytokine responses to Meth exposure were dynamic. For example, while CXCL16 was
strongly up-regulated at 2 h of exposure, at the 6 h time point the levels subsided back to
control level. Notably, by 24 h the majority of the cytokines returned back to control levels. In
accordance with previous studies, we performed viability assays of Meth-treated macrophages
for up to 48 h (Fig. 2.2). There was a slight trend of decreased viability however, we did not
observe significant changes in any of the time points.
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2.3.2. Meth promotes a pro-inflammatory macrophage phenotype
Based on the classification of pro-inflammatory and anti-inflammatory functions of
cytokines, the pattern of cytokine expression after Meth exposure shifted the phenotype of
macrophages towards pro-inflammatory (Fig. 2.3) [16-18]. Overall, the changes in cytokines
expression peaked at 2 h after exposure to a single dose of Meth and persisted for 6 h,
eventually subsiding by 24 h (Table 2.3). Next, we focused our study on TNF, CXCL1 and IL-8.
Each was up-regulated in an increasing manner at stepwise concentrations of Meth (Fig. 2.4).
The effect of Meth at higher concentrations such as 500 μM or 1 mM, was masked, possibly due
to a small yet significant decrease in cell viability, which was not observed in concentrations up
to 100 μM (Fig. 2.2). Therefore, to prevent the cytotoxic effects of Meth and cytokine-induced
cytokine expression, all further experiments were conducted at 2 h of Meth exposure at 100
µM.
2.3.3. Meth down-regulates CCL7 expression
Based on our array results showing a robust down-regulation of CCL7 by Meth and given
the importance of CCL7 in innate immunity we further looked at signaling pathway upstream of
CCL7 expression [13, 21]. CCL7 is induced by TLR9 activation in a MyD88-dependent pathway
and utilizes AP-1 and NF-κB as transcription factors [21]. First, to confirm the array data we
performed RT-qPCR to investigate whether CCL7 is down-regulated by Meth exposure in a
concentration dependent manner. Indeed, increased concentrations of Meth from 1 to 100 μM
at 2 h of exposure led to a statistically significant reduction in CCL7 mRNA expression (Fig. 2.5
A). It has been shown in vivo that the expression of CCL7 and INF-α is dependent on activation of
TLR9 [21]. Therefore, we performed experiments to see if Meth would block TLR9 mediated
signaling. To do this we used CpG ODN, an agonist of TLR9, which is also used as a surrogate for
an infection model of bacterial DNA. We measured the expression of CCL7 in the presence of
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Meth and CpG ODN for 2 h, and used INF-α as a positive control. As expected, treatment with
the TLR9 agonist (CpG ODN) up-regulated expression of CCL7 and IFN-α. CCL7 was downregulated when macrophages were treated with only Meth, at similar levels to our timedependent profiling experiment. Meth also attenuated the CpG ODN-induced expression of
both, CCL7 and IFN-α (Fig. 2.5 B-C).
2.3.4. Meth affects TLR9 signaling pathway
The attenuation of CCL7 and IFN-α expression by Meth during TLR9 activation suggested
that Meth reduces viral defense. CCL7 and IFN-α utilize several of the same signaling
components downstream of TLR9, but the expression of each is dependent on different
transcription factors, NF-κB and IRF7 respectively [22, 23]. Thus, we hypothesized that in order
for both CCL7 and IFN-α to be differently expressed, the inhibition caused by Meth was
occurring at or upstream the common TRAF3/6 signaling factors that are used by both cytokines
(Fig. 2.8.). First we investigated if the levels of TLR9 changed upon Meth exposure. Neither
mRNA expression nor protein levels of TLR9 were significantly changed compared to mock CpG
treatment, but there was a trend of reduced TLR9 expression after Meth treatment alone (Fig.
2.6). Meth did, however, decrease the expression of TLR9 in CpG ODN treated cells to the level
of control cells.
2.3.5. Effect of Meth on the transcriptional regulator NF-κB
There are several putative binding sites in the promoter region of CCL7 for the
transcription factors, AP-1 and NF-κB. A possible mechanism of how Meth down-regulates the
expression of CCL7 is Meth reduces the abundance of the transcription factors for CCL7.
Therefore, we measured the protein levels of the NF-κB subunit, p65, from Meth exposed
macrophages up to 48 h and observed no change over time (Fig. 2.7). Although these results
informed us that overall levels of NF-κB do not change in Meth treated cells, it could still
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interfere by preventing the translocation of NF-κB and making it less available at the promoter.
The nuclear localization signal of NF-κB is masked by IκB and the inhibition of NF-κB by IκB is
released when IκB is phosphorylated and degraded. Meth preventing the phosphorylation or the
degradation of IκB warrants further investigation as well as the availability of the other CCL7
transcription factor, AP-1.
2.3.6. DNA methylation in the promoter region of CCL7 does not contribute to
suppression
Changes in DNA methylation might be one potential mechanism that Meth induces to
alter gene expression. To investigate whether such a mechanism is occuring on CCL7 expression,
we measured the DNA methylation status of two CpG islands in the promoter region of CCL7.
These islands are located on chromosome 17:(hg19) at positions 32596886 and 325971103. One
CpG island is located at -349 relative to the promoter start site while second one is located at
position -132. We have found that in mock treated macrophages for 2 h at the -349 position is
hypermethylated at the level of 96% while -132 position is hypomethylated at the level of 2%
(Table 2.2). The levels of methylation of both CpG islands were not affected by addition of Meth
or treatment with CpG ODN, indicating that Meth does not regulate the methylation status of
CCL7.

44

Gene

Sense Primer (5’ to 3’)

Anti-sense Primer
(5’ to 3’)

Sequencing Primer
(5’ to 3’)

PCR
(bp)

Anneal
C

CCL7-1

AAGTTATTAGGATTTAAGATA
GTGAAGAA

TATATAAAAAATATTCCCCTTTTC
CCTTT

AAGTTTGAATGTTTTTTTGT
GGAT

133

58

CCL7-2

TGATAATAGTTATAGATTATAT
ATTGTGG

TCTACTAAACCAATACACTTCAA
TAAAAA

GTTTTAGTTGAAAAATAGG
TTAGTT

147

58

Table 2.1. Parameters for DNA pyrosequencing. Primers for CCL7 around two CpG
islands (CCL7-1 and CCL7-2), the size of the PCR product, and optimal annealing
temperature.
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Table 2.2. Percentage of methylated DNA around both CpG islands for CCL7
promoter. Macrophages were either mock treated with 1 µg/mL of non-stimulatory CpG
(ODN 2243), 100 µM of methamphetamine, or 1 µg/mL of stimulatory CpG (ODN 2216)
for two hours. Then harvested for DNA and analyzed for methylation. Sss1 methylated
and lymphocyte DNA served as the positive and negative control, respectively
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Table 2.3. RNA expression profile of immune mediators over time from Methexposed macrophages. RT-qPCR analysis of mediators that illicit an immune response
including receptors, growth factors, interleukins, and cytokines were measured after
47

macrophages were exposed to Meth for either 2, 6, or 24 hours. The average fold
change represented in each box is from Meth treated macrophages relative to
corresponding time control from 3 biological replicates. Red positive box indicates an upregulation while a green negative box indicates a down-regulated gene. Fold changes
are normalized to the housekeeping gene GAPDH.
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Figure 2.1. THP-1 monocyte to macrophage differentiation. THP-1 monocytes, a
human monocytic leukemia cell line, were differentiated according to ATCC guidelines
with 200 nM of PMA on days 0 and 2 until day 4. Cells rest in PMA-free media from day
4 to 6, after which they are considered macrophage-like and exposed to treatments.
Similar to in-vivo macrophages, THP-1 macrophages are terminally differentiated and do
not proliferate. 10X objective. Arrowhead ( ) symbolize spherical, round monocytes.
Arrows (↑) point to processes of macrophages.
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Figure 2.2. Viability of macrophages at different times and concentrations of Meth
exposure. (a) Macrophages treated with either control (complete RPMI media) or 100
µM of Meth for 2, 6, 24, and 48 hours. Viability assessed by MTT assay and normalized
to the respective time control and to a positive control. (b) Macrophages were treated
with varying concentrations of Meth (1-1000 µM) for 2 h. Viability assessed by MTT
assay and normalized to control (0 µM). Positive control cells were treated with 1%
Triton X-100. Data are represented as the mean ± SD. An asterisk (*) indicates p<0.05
by a Student’s t-test.
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Figure

2.3.

Characterization

of

immune

mediators

from

Meth-exposed

macrophages. Macrophages were treated with 100 µM Meth for either 2 or 6 h. After
treatment, total RNA was isolated and expression of chemokines, interluekins, and
cytokines was profiled by RT-qPCR. Cytokines are defined as either pro-inflammatory
(a, c) or anti-inflammatory (b, d) and organized in decreasing order of regulation levels.
Fold changes are normalized to the housekeeping gene GAPDH.
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Figure

2.4.

Concentration

dependence

on

mRNA

cytokine

expression.

Macrophages were exposed to 0-100 µM methamphetamine for 2 h and select cytokines
were chosen for relative quantification by RT-qPCR. Baseline expression of each
cytokine corresponds to control (0 µM) and represents a fold expression of 1. Data are
represented as the mean±SD fold expression of 3 independent experiments. An asterisk
(*) indicates p<0.05 by a Student’s t-test. All fold change is normalized to the
housekeeping gene GAPDH.

52

Figure 2.5. Methamphetamine inhibits the expression of CCL7. (a) RNA expression
of CCL7 was measured by RT-qPCR in macrophages treated with varying
concentrations of methamphetamine (0-100 µM) for 2 h. (b, c) Macrophages were
exposed to 100 µM or 1 µg/mL CpG (CpG oligodeoxynucleotides) for 2 h. Expression of
IFN-α is induced by activation of TLR9 by CpG and used as a positive control. Data are
represented as the mean±SD fold expression of 3 independent experiments. An asterisk
(*) indicates p<0.05 by a Student’s t-test. Fold changes are normalized to the
housekeeping gene GAPDH.
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Figure 2.6. Methamphetamine attenuates the CpG-induced expression of TLR9. (a)
Representative image of immunocytostained macrophages for TLR9 (green) at 1:500
and DAPI (blue) at 1 µg/mL that were either mock treated with 1 µg/mL non-stimulatory
CpG (ODN 2243), 100 µM of methamphetamine, or 1 µg/mL of stimulatory CpG (ODN
2216) for 2 h. 40X oil immersion fluorescent microscope (b) Immunostaining for TLR9
antibody protein were quantified using Image J. Data are represented as the mean±SD
fluorescent intensity per area of 3 independent experiments. (c) Total RNA from treated
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macrophages was converted to cDNA and the levels of TLR9 determined by RT-qPCR
relative to the mock treated macrophages. An asterisk (*) indicates p<0.05 by a
Student’s t-test. Quantification was normalized to the housekeeping gene GAPDH, n=3.
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Figure 2.7. Methamphetamine does not alter protein levels of the pro-inflammatory
transcription factor, NF-κB. Macrophages were either mock treated (RPMI media) or
treated with 100 µM methamphetamine for 1, 2, 6, and 24 h. Western blots from whole
cell lysates were blotted for anti- p65 (1:1000) or anti-actin (1:2000) for a loading control.
This figure is a representative Western blot of 3 biological replicates.
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Figure 2.8. Signaling pathway of TLR9 by CpG activation and summary of results.
Single stranded unmethylated CpG (cytosine phosphate guanine) is endocytosed and
stimulates TLR9 (Toll-like receptor 9) signaling. Macrophages were treated with CpG or
Meth and CpG for two hours. Numbers in this figure indicate a description for each
experiment. (1) TLR9 mRNA and protein was up-regulated after CpG treatment. (2)
Meth decreased the CpG induction of TLR9 back to control levels. (3) Activation of TLR9
in combination with an IRAK1/4 chemical inhibitor leads to the inhibition of CCL7
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transcription. Although it shows that the regulation of CCL7 is utilizing IRAK1/4 as
intermediate, we found no evidence of Meth effecting the overall protein expression of
IRAK1 or the phosphorylation of IRAK1 at Thr387. (4) Total levels of IkB protein did not
decrease after 1 hour of Meth exposure nor up to 24 hours. This, however, was similar
to other studies where degradation of IkB was found as early as 15 min for certain
treatments. (5) Meth does not change the overall levels of NF-κB in the cell over time,
however one possibility is that Meth prevents the translocation of NF-κB thus making it
less available at the promoter. (6) CpG treatment moderately (5-10 fold) up-regulated
the expression of CCL7 and IFN-α when compared to mock treatment. (7) Yet, Meth and
CpG together down-regulated both cytokines. (8) Pyrosequencing results of either
treatment, CpG or CpG and Meth, showed no change in DNA methylation at either CpG
island of the CCL7 promoter region excluding this as mechanism of transcription
regulation.
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2.4.

Discussion
The effects of Meth could be acting on the extracellular receptors, intracellular signaling

molecules, or in the nucleus. We focused these studies on one signaling pathway, the MyD88mediated TLR9 signaling pathway. The investigation started at the utmost upstream location,
examining changes in the TLR9 mRNA expression and protein levels. The effects of Meth in
conjunction with CpG treatment can be seen in red circles whereas the remaining is of the
effects of CpG alone (Fig. 2.8). First, a small down-regulation of TLR9 by Meth was observed.
However, it was not sufficient to explain the strong down-regulation of CCL7 and INF-α. This
suggested that Meth was affecting signaling mediators or transcription regulation further
downstream of TLR9. Therefore, we measured protein of signaling factors such as IRAK1, IκB and
IRF7 but found no changes in total levels or phosphorylation at key regulatory sites (data not
shown). Next, we found that Meth does not affect the expression of a key transcription factor,
NF-κB. Furthermore, the levels of DNA methylation in the promoter region of CCL7 did not
change in the presence of Meth and or CpG treatment. Hence, we might expect to see either an
absence of enhancing transcriptional complexes or an increase in the silencing transcriptional
complexes found around the CCL7 start site. To measure the changes in either the silencing or
enhancing transcription complexes, we would first use chromatin immunoprecipitation (ChIP)
for either NF-κB or AP-1 transcription factors and PCR for CCL7. Next, use a mass spectrometry
approach to identify the differences in Meth exposed macrophages to control treated cells from
the ChIP pull down. The exact mechanism of how Meth affects TLR9 or other MyD88-mediated
signaling pathways will require more extensive studies.
Macrophages respond rapidly to external stimuli and one such response is the release of
cytokines, which plays a critical role in recruiting other immune cells to initiate the innate and
adaptive immune response. Changes in the production of cytokines can have autocrine and
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paracrine signaling effects as well as, can determine activation and phenotypic polarization of
these cells. Generally, polarized macrophages can be classified as an M1, classically activated
macrophage or M2, alternatively activated macrophage however, there is a spectrum of
activation states in between these two [25, 26]. Thus, the phenotype of macrophage activation
under specific pathological condition or stimulation will be best described by profiling cytokine
secretion among other factors [27]. Classically activated (M1) macrophages will be polarized in
response to stimulation by IFN-γ and LPS and characterized by their ability to secrete proinflammatory cytokines such as TNF-α, IL-1β, and IL-12 [28, 29]. On the other hand, the M2
phenotype, which includes the M2b phenotype, is considered immune regulating by expressing
high levels of IL-10, CXCL1, and TNF-α and can be induced by TLR ligands [30]. Based on our
results, the mRNA profile of cytokine expression in macrophages exposed to Meth most closely
fit an M2b phenotype, more so than other types. However, additional cell surface markers and
other chemical molecules are needed to completely characterize the phenotype of Methexposed macrophage.
One principal finding of the present study is that Meth induces the up-regulation of proinflammatory cytokines (Fig. 2.3).The pro-inflammatory effect of Meth has been previously
demonstrated in literature by measuring a few pro-inflammatory cytokines like TNF-α, IL-1β,
and IL-8; however this is the first study profiling 84 cytokines and chemokines as a systematic
study [12, 19, 20]. Also, these studies were focused on the LPS-induced response mimicking
bacterial infection and were limited in scope by the number of cytokines measured [12, 31].
Therefore, in our study we profiled 84 cytokines and chemokines, which provided a more
comprehensive overview of macrophage polarization. Indeed our results showed that besides IL10 and the modest expression of three others (CCL19, CCL21, and IL-4), macrophages showed
pro-inflammatory phenotype over a 24 hour time frame of Meth exposure. One of most striking
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observations resulting from profiling the cytokines over time was the strong down-regulation of
CCL7 within 2 hours of Meth treatment indicating TLR9 signaling as a target pathway for this
suppression [21]. This notion was reinforced further by our observations that Meth also
suppresses the expression of IFN-α upon CpG ODN treatment. The CCL7 response was time- and
concentration-dependent and, as anticipated, the onset of the Meth effect is rapid in
macrophages.
Many of the pro-inflammatory cytokines such as TNF-α, IL-8, IL-1, and CXCL1 are
regulated by NF-κB. In particular, IL-6 and IL-8 expression after Meth have been investigated for
the dependence on NF–κB in other model systems. In these experiments, Meth up-regulated IL8 and IL-6 in astrocyte cell line after 3 days of exposure [32]. The subcellular protein levels of NFκB was measured over a span of 6 hours and, as expected to induce IL-8 and IL-6, was found to
translocate to the nucleus. The authors also reported that PI3K/Akt, which is upstream of the
activation of NF-κB, is involved in the Meth-induced expression of IL-6 and IL-8. In a similar study
using gp120 transfected astrocytes, Meth was found to synergistically increase IL-6 and IL-8
mRNA and protein [33]. In our study, we found a concentration dependence effect of Meth on
IL-8 but we did not measure IL-6 since it was not found statistically significant in the initial mRNA
screening of time-dependent Meth exposed macrophages. Overall, the induction of cytokines is
initiated by multiple pathways depending on the stimulus and even overlap by using the same
signaling factors in different pathways thus, adding to the complexity of delineating the pathway
for Meth-induced alterations of cytokine expression.
Since Meth users show increased susceptibility to various infections, we posit that the
TLR signaling pathways, which orchestrate the clearance of infections, is hindered under Meth
exposure [1, 34]. The significance of our results is further reinforced by previous studies showing
that the expression of CCL7 is critical for immunity against cryptococcosis [7, 21]. While
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infections with this fungus are rarely seen in those with fully functioning immune systems, it is
the most common cause of fungal meningitis in AIDS patients, killing more than half a million
people worldwide per year [35]. After the fungi, cryptococcus neoformans, are phagocytosed by
alveolar macrophages it disseminates from the lungs to other parts of the body, including the
brain regions to give rise to fungal encephalitis and meningitis [36]. Thus, the Meth-induced
inhibition of CCL7 would prevent the recruitment of monocytes and eosinophils that facilitate
the clearance of the fungal infection [21].
In summary, we conclude that Meth is immunosuppressive and inhibits TLR9 signaling
and CCL7 and IFN-α expression. The cytokine environment produced by the Meth-exposed
macrophage can induce a T-cell response and change the phenotype of naïve T-cells to
regulatory T-cells, Th17, Th1, or Th2 helper cells [37-39]. Changes in the ratios or balance of
supportive and detrimental T-cells subtypes can be pathological [40, 41]. In addition, the other
aspect of the adaptive immune response, antibody production, is also impaired by Meth. In
mice, the levels and the type of Ig antibodies produced were hindered in mice that were given
increasing doses of Meth [8]. Lastly, Meth hinders several roles of macrophage function
particularly cytokine expression and thus, greatly prevents the macrophage’s ability to respond
for proper innate and adaptive immunity.
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Chapter 3

Alterations in Expression of HDACs and Levels Posttranslational Modifications in HIV-1-infected,
Meth-exposed Macrophages Treated with cART
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3.1.

Introduction

3.1.1. Discovery of HIV and subsequent pandemic
The first official documentation published by the US Centers for Disease Control
and Prevention (CDC) on 5th June 1981 entitled “Pneumocystis Pneumonia – Los
Angeles” outlined five cases of young gay men hospitalized with pneumonia,
cytomegalovirus, and disseminated candida infections [1]. A month later, the New York
Times reported that a total of 41 homosexual men had been diagnosed with Kaposi ’s
sarcoma, a rare skin cancer [2]. This unknown disease was spreading rapidly and at the
end of 1981, 5 to 6 new cases of the disease were being reported each week [3]. It was
unclear how young and previously healthy individuals were succumbing to such deadly
opportunistic infections but assumed the condition was limited to the gay population,
hemophiliacs, intravenous drug users, and immunocompromised individuals. In July
1982, at a meeting in Washington, D.C., the condition or disease was termed Acquired
Immune Deficiency Syndrome (AIDS) [3, 4]. The CDC reported that the incidence of
AIDS had risen from less than 6 per week to an average of one to two cases being
diagnosed in the USA every day [5]. By the end of 1983 the number of AIDS diagnoses
reported in the USA was 3,064 with an alarming 42.2% of them deceased [6]. In 1984,
French scientists isolated the Human Immunodeficiency Virus (HIV) from the lymph
node of infected patients that was the causative agent responsible for AIDS pandemic
seen in earlier years [7].
HIV infection became a global pandemic with an estimated 35.3 million cases
worldwide and 1.4 million people of those infected live in North America as of 2013 (Fig.
3.1.) [8, 9] HIV has since its discovery been subcategorized into two types, HIV-1 and
HIV-2. HIV-1 is the most common type of the virus, while HIV-2 is predominately in
Western African [10].
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Figure 3.1. Number of People Living with HIV as of 2013 (Source: UNAIDS)

3.1.2. HIV structure and life cycle
HIV is a lentivirus of the retroviridae family. Lenti or lente translates to ‘slow’ in
Latin and means HIV can be latent for a long period of time before it becomes active and
pathogenic. The retroviridae family of viruses means the genetic material of HIV is RNA
(in the case for HIV, two single stranded RNA molecules) as opposed to DNA. The viral
genome consists of 9 genes (gag, pol, env, tat, rev, nef, vif, vpr, and vpu) and 15 distinct
proteins [11]. There are six structural proteins: matrix (MA), capsid (CA), nucleocapsid
(NC), p6, glycoprotein 120 (gp120) and gp41; three enzymes: protease (PR), reverse
transcriptase (RT), and integrase (IN); two essential proteins: Tat, and Rev and four
additional proteins called accessory proteins: Vif, Vpr, Vpu, and Nef, of which Rev and
Tat are essential since they are compulsory for the transcription of daughter virus
particles [12, 13]. The others are accessory as they are dispensible for replication in
vitro, but required for pathogenesis in vivo.
HIV is packaged into virons that contains all necessary components for the virus
to travel throughout the bloodstream and infect other cells. The formation of virions can
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be divided into three stages: assembly, in which the viral proteins are created and
essential components are packaged; budding, wherein the virion crosses the plasma
membrane and obtains its lipid envelope; and maturation, where the virion structure
changes and becomes infectious [14]. An HIV virion is approximately 100 to 150 nm in
diameter and is made up of a viral envelope and viral core. The viral envelope

Figure 3.2. The Steps of the HIV Life Cycle. (Source: Adapted from Nature Reviews
[15])
is a lipid bilayer derived from host’s plasma membrane during budding. A number of host
cell proteins and viral specific glycoproteins are associated with the envelope. These
viral glycoproteins, both encoded by the HIV env gene, are glycoprotein 120 (gp120),
which is non-covalently linked to the transmembrane glycoprotein 41 (gp41). The core
(or capsid) of the virion consists of a cone-shaped protein p24 and protects the viral
genome and the three enzymes RT, PR, and IN that are essential for the survival and
infectivity of HIV [16].
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The HIV life cycle starts with HIV gp120 on the surface of the virion attaching to
the CD4 co-receptor on the host cell. A conformational change in gp120 allows further
interaction with either, CXCR4 (X4) or CCR5 (R5) co-receptors [17]. Once gp120
interacts with both CD4 and either chemokine receptor it results in the insertion of the
fusion peptide into the host cell membrane to initiate fusion of the viral and host cell
membranes. The viral core is then released in to the cytoplasm of the host [18]. Next,
the viral RNA is reversed transcribed by the prepackaged viral enzyme RT. The cDNA of
HIV translocates to the nucleus using a number of host’s proteins as chaperones and is
integrated into the host DNA using IN [19, 20]. When activated, the proviral DNA is
transcribed and translated. Two of the first viral proteins to be translated to positively
regulate transcription are Tat (trans-activator of transcriptional) and Rev (regulator of
expression of virion proteins). The large polypeptide chains comprising of viral core
envelope (Env) and gag proteins are cleaved in to smaller fractions. HIV RNA, the viral
Env protein, the Gag polyprotein, and the three viral enzymes: PR, RT, and IN assemble
near the host’s plasma membrane and results in budding of a new infectious particle [15]
(Fig. 3.2.).
3.1.3. Common therapy for HIV-1 infection
The treatment strategies for HIV positive individuals are designed to primarily
target viral enzymes as well as virus entry to prevent the progression of the various
stages of the viral life cycle. The FDA approved drugs for HIV fall in to 6 different
classes: non-nucleoside reverse transcriptase inhibitors (NNRTI) nucleoside reverse
transcriptase inhibitors (NRTI), protease inhibitors (PI), fusion inhibitors, entry inhibitors
(also called chemokine receptor antagonists), and integrase strand transfer inhibitors
(INSTI). NRTI were the first class of drug to be approved by the FDA and inhibits RT
with modifed nucleosides that bind to viral DNA and halt the elongation by RT. Tenofovir
(TDF), trade name Viread, is an FDA approved NRTI and although being synthesized in
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1984, it was not approved until 2001. However, TDF is on the World Health
Organization's (WHO) List of Essential Medicines for preventing and treating HIV and
chronic Hepatitis B, a common co-infection [21-23]. Another common and NRTI is
Emtricitabine (FTC) and is available as a monotherapy or as a fixed dose together with
TDF, trade names Emtriva and Truvada, respectively [24]. During the mid-90s, the PI
class of drug was introduced. As the name indicates, PI prevents viral replication by
selectively binding to PR, which is critical for the cleavage of protein precursors into the
mature infectious proteins therefore, no active enzymes or budding can occur.
Atazanavir (ATV), trade name Reyataz®, was the first approved PI for once daily dosing
and is also on the WHO List of Essential Medicines.
Due to HIV mutating and development of drug resistance, the standard regimen
of treating HIV is with combinational antiretroviral therapies (cART) using drugs from
different classes, two NRTI/NNRTI and one PI/INSTI [25, 26]. The newer classes of
drugs that are also useful in cases when drug resistance occurs against PI and RT
inhibitors are entry inhibitors and INSTI [27]. The entry inhibitors in particular target the
different stages of HIV entry, binding to either the CD4 or CCR5 receptors, or fusion of
gp41, onto CD4+ cells. Maraviroc and Enfuviritide are currently approved members in
this group. Following the success of triple combination therapy, morbidity and mortality
decreased drastically, making what was once a death sentence into a chronic condition
where the life expectancy is now almost equal to healthy averages (~70%) [28, 29].
3.1.4. Meth use and HIV risk
HIV-1 infection and Meth addiction are serious and common comorbidities [30,
31]. Prevalence of both comorbidities is hard to determine since the prevalence is reliant
on the region, the person’s sexual orientation, whether or not the use of Meth is chronic
or sporadic, and whether or not Meth is injected [32, 33]. Regardless of why HIV positive
patients abuse Meth, it is often accompanied with unsafe sex practices as the effects of
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Meth result in increases in sexual libido while decreasing judgment and inhibition,
thereby increasing risk for HIV transmission [34]. Another issue with concurrent Meth
use and positive HIV status is a decrease in adherence to HIV treatment and medical
visits [35]. Frequent Meth use has also been associated with increased risk for
antiretroviral resistance, particularly to NNRTIs and possible fatal interactions when used
with PI [36-38]. All the risk factors taken together is shocking as Meth use can increase
the risk for new HIV transmission cases through sexual activity and also contribute to
poorer health outcomes in HIV-infected individuals.
Meth can be smoked, ingested (orally or anally), or injected, though the latter
holds an increased risk in the case of sharing needles to spread HIV and other blood
borne viruses [21, 39]. An estimated 20-40% of injecting drug users are HIV positive
equating to about 3·0 million (range 0·8–6·6 million) people worldwide [33]. Although the
percentage of injecting drug users includes other types of illicit drugs besides Meth, the
astounding number is a major issue and risk to global public health.
3.1.5. HIV-1 latency and role of epigenetics
Epigenetics is the study of cellular factors and the mechanisms that help control
gene expression that are not caused by the changes in DNA sequence. Research shows
that epigenetics is, at least partially, contributes to inheriting addictive behaviors, aging,
neuronal plasticity, and memory formation [40-43]. Post-translational modifications
(PTM) to the histone N-terminal (“histone tails”) and DNA methylation are the two
epigenetic mechanisms that regulate gene expression. The number and type of PTM
(acetylation, methylation, phosphorylation, and mono- di-, or tri-) as well as location
(which residue), and combination can indicate gene transcription or repression. This is
referred to as the histone code [44, 45]. For example, methylation of histones can occur
on lysine or arginine residues and can be mono- (Me), di- (Me2), or trimethylated (Me3).
Acetylation (Ac) occurs on lysines but due to the neutralization of ε-amino group, only
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one acetyl moiety can occur per lysine. Phosphorylation (P) occurs on serine and
threonine residues and similar to acetylation can occur only once but for a different
reason, the presence of one hydroxyl group. Ubiquitination (Ub) can occur on lysines
and is complex because there can be one (mono-) or long chains of Ub
(polyubiquitinated). Given the number of different types of PTM and number of amino
acids they may or may not occur on and considering them occurring on multiple residues
simultaneously, the number of possibilities to decipher the histone code is extensive.
However, using a reductionist approach, the fundamentals have begun to be
determined, including how a single PTM alters transcription, or if enzymes demonstrate
specificity to which histone substrate [46-48]. For example, acetylation of lysine
residues, although not always, will activate transcription whereas, a non-modified lysine
inhibits transcription as well as DNA methylation [49, 50].
Of particular interest are the epigenetic mechanisms regulating HIV expression.
The most studied PTM and mechanism in regards to HIV transcription is acetylation and
deacetylation. The enzymes that accomplish the addition and removal of acetyl groups
are called histone acetyltransferases (HAT) and histone deacetylases (HDAC),
respectively. HDACs are classified as Class I or Class II. HDACs are divided and
grouped together based on the sequence homology to the yeast counterparts however,
a big difference between the localization of the two classes. Class I HDACs (HDAC1, 2,
3, and 8) are primarily found in the nucleus whereas, Class II HDACs (HDAC4, 5, 7, and
9) shuttle between the cytosol and nucleus. One HDAC in particular, HDAC1, was found
to silence HIV expression but when incorporated into virions help facilitated entry of HIV
into other cells [51, 52]. Even though cART has been able to control the virus to below
detection levels, latent HIV exists in long-lived memory CD4+ T-cells and macrophages
and prevents complete eradication of infection [53, 54]. Therefore, studies have used
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HDAC inhibitors (HDACi) to open the chromatin and reactivate the expression of viral
genes so that new therapies can target latently infected cells [55-57].
Epigenetic mechanisms are not only of interest to the field of HIV research but as
mentioned previously, studied in the cases of drug addiction by itself or with both
comorbidities (HIV and addiction) [40, 58]. Changes in gene transcription in the midbrain
seen after chronic Meth exposure have been correlated with increases in the histone
PTM acetylation as well as a decrease in HDAC1 protein [59-62]. There is evidence that
epigenetic mechanisms regulate the viral genome and how that is altered in Meth
abusers still needs to be determined so that reservoirs can be depleted and HIV finally
eradiated. Therefore, the goal of our study is to identify the key factors involved in
affecting HIV transcription using macrophages as a model of the immune function
dysregulation in Meth abusers on cART.

3.2.

Materials and Methods

3.2.1. Cell culture and sample preparation
Primary human monocytes were obtained through leukophoresis from donors
who were seronegative for HIV-1, HIV-2, and hepatitis B virus. These monocytes were
purified using counter-current centrifugal elutriation and cultured at a final concentration
of 1 million per mL in macrophage serum-free medium (MSFM) (Invitrogen; Carlsbad,
CA)[63]. MSFM was supplemented with a 1% HEPES buffer (4-(2-hydroxyethyl)-1piperazineethanesulfonic acid)) (Invitrogen); 1% Nutridoma (Roche Diagnostics GmbH;
Indianapolis, IN), and 10 ng/mL Macrophage-colony stimulating factor (MCSF)
(PeproTech; Rocky Hill, NJ). Half of the media volume was exchanged every other day.
After seven days of differentiation monocytes are considered monocyte-derived
macrophages (MDM) and no longer require MCSF and therefore, HIV-1ADA infection was
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diluted in new MSFM at a multiplicity of infection of one (MOI:1) for 4 h at 37°C. After,
virus media is removed and replaced with fresh MSFM with the above defined
supplements. On day 10, Meth (Sigma-Aldrich; St. Louis, MO) added at a concentration
of 100 µM. Two days later on day 12, full media was removed and ATV, TDF, and FTC
(henceforth referred to as cART) was added to fresh media, each at an efficacious
concentration of 5 µM. All media was removed and cells were washed three times with
phosphate buffered saline (PBS; HyClone; Logan, UT) before conditions were harvested
on day 17 (Fig. 3.3.). Macrophages were lysed for RNA, whole cell lysates (WCL), or
fractionated into subcellular parts using the Qproteome Nuclear Protein Kit (Qiagen;
Germantown, MD) according to manufacturer’s protocol (Fig. 3.4.). To obtain protein
from WCL, cells were scraped in PBS and pelleted by centrifugation at 1000 x g for 5
min at 4°C and re-suspended in 300 µL per 106 cells of lysis buffer. Lysis buffer
contained 4% (w/v) SDS (Bio-Rad; Hercules, CA), in 0.1 M Tris-HCl (Fisher Scientific;
Fair Lawn, NJ), 0.1 M DTT (Promega; Madison, WI) and 1X Protease Inhibitor Cocktail
(Sigma-Aldrich). Cells were boiled at 95°C for 5 min, allowed to cool, and 100 units/mL
Benzonase Nuclease (Merck KGaA; Darmstadt, Germany) was added. All protein
samples were quantified using Pierce 660 Assay as per the manufacturer’s protocol
using 50 mM ionic detergent compatible reagent (Thermo Scientific; Rockford, IL).
3.2.2. Quantification of HDAC levels and histone PTMs by Western blot
Five micrograms of cytosolic, nuclear, or WCL proteins were loaded onto TrisGlycine gels (Invitrogen) and separated using one-dimensional electrophoresis. Proteins
were immediately transferred to a PVDF membrane (Bio-Rad; Hercules, CA) and
blocked overnight at 4°C in 5% milk in Tris-Buffered Saline supplemented with 0.2%
Tween 20 (TBST) (both from Fisher Scientific). Nuclear fraction was used to blot for
HDAC antibodies that were from a commercial source: HDAC1-6 (1:1000) for 1 h and
horseradish peroxidase (HRP) secondary (1:1000) at room temperature for 1 h (Cell
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Signaling Technologies; Beverly, MA). Washes were performed after primary and
secondary antibodies using TBST three times for 5 min each. Three PTMs were studied,
acetylation on lysine 5 histone 4 (H4K5ac), acetylation on lysine 9 histone 3 (H3K9ac),
and acetylation on lysine 18 histone 3 (H3K18ac) (all from Abcam; Cambridge, UK) all at
1:1000. Each of the three PTM primary antibodies were incubated at 4°C overnight.
Three washes for 5 min each were performed with TBST before and after adding HRP
secondary antibody (Jackson ImmunoResearch; West Grove, PA) at 1:20000 at room
temperature for 30 min. Each blot was incubated at a 1:1 ratio with TMA-6 Solution A
and B enhanced chemiluminescence (Lumingen; Southfield, MI) in the dark for 1 min
and exposed for 3 seconds. The density of the band was calculated on the Kodak
CareStream Imaging System Image. Three biological replicates/donors were used for
quantifying HDACs. Student’s t-test was performed on the intensity valued after
normalization to the intensity of actin.
3.2.3. RNA extraction and relative quantitative PCR
Cells were lysed directly in the culture dish with Trizol Reagent (Life
Technologies; Carlsbad, CA). RNA was resuspended in 10 mM Tris (Pro-Pure, Solon,
OH) and 1 mM EDTA (Fisher Scientific), pH 8.0 in RNase free water. One microgram of
RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit
(Life Technologies) per the manufacturer’s protocol. The primers used were human
HDAC1 and HDAC6 (both Integrated DNA Technologies; Coralville, IA) and human
GAPDH primers were used for normalization (Applied Biosystems; Warrington, UK). The
relative abundance of each gene was calculated using the comparative CT method [64]
3.2.4. Imaging of HDAC1 colocalization by confocal microscopy
Primary human MDM were cultured in 8-well chamber slides at a density of
500,000 cells per well. Cells were exposed to either MSFM for control or 100 µM Meth
for 24 h at 37°C. Wells were washed 3 times with Tris-buffered saline (TBS, Sigma78

Aldrich), fixed with 4%

paraformaldehyde (PFA, Sigma-Aldrich) for 30 min,

permeabilized and blocked simultaneously with 0.1% Triton (Thermo Fisher; Waltham,
MA) and 10% normal goat serum (NGS, Vector Laboratories; Burlingame, CA) in TBS
and then quenched with 50 mM NH4Cl (Sigma-Aldrich) for 15 min. The cells were
washed with 0.5% Tween (Thermo Fisher) in TBS (TTBS) and incubated at (1:100) for
the primary antibodies rhodamine-conjugated phalloidin (Life Technologies) and 1 µg/mL
of HDAC1 (Abcam) in 10% NGS for 1 h at 37°C. The cells were then washed with TTBS
and incubated with the secondary antibody conjugated to Alexa Fluor 488 for 45 min at
37°C. One μg/mL of DAPI (Invitrogen) for 5 min was used to stain nuclei and after one
wash with water and one wash with TBS, one drop of Prolong Gold (Invitrogen) was
added before the slides were cover slipped. Images were captured using the Zeiss Meta
510 confocal microscope (Carl Zeiss, Inc., Thornwood, NY, USA) and Zen lite Imaging
software (version 2011). Ten parallel replicates were measured for each condition using
ImageJ software.

3.3.

Results

3.3.1. Quantification of HDACs
Given the ambiguity for the roles of HDACs in HIV or Meth use in macrophages,
we measured the protein levels of some HDACs from Class I and Class II in an unbiased
manner in all 8 conditions (Fig. 3.4). Cells were fractionated into nuclear and cytoplasmic
proteins to decipher the localization of each. HDAC1-4 were detected in both the cytosol
(Fig. 3.6.) and the nucleus (Fig. 3.7.). Surprisingly, HDAC5 and 6 were never detected in
any of the three donors. The only HDAC with a statistical difference in expression
compared to control cells was HDAC1 in Meth treated MDM, although there was also a
trend for decreased HDAC1 in the nucleus (Fig. 3.8.). To confirm the localization of
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HDAC1 protein, we used confocal microscopy to visualize and quantify HDAC1 in Meth
exposed MDM. In the previous quantitative Western blot experiments MDM were
exposed for 48 h, the confocal images were taken after only 24 h of exposure. Even so,
HDAC1 was found to be decreased significantly compared to control (or mock treated
macrophages) (Fig. 3.9.). Next, we sougt to determine the mechanism of decreased
HDAC1 protein either decreased transcription, altered PTMs, increased degradation, or
both altered PTMs and degradation [66]. To do this we first isolated the total RNA and
performed RT-qPCR on HDAC1 and HDAC6. We observed that HDAC1 was highly
expressed in control cells (data not shown) but drastically decreased in Meth treated
MDM. In contrast, HDAC6 levels barely increased compared to control cells (Table.
3.1.). In order to overcome the donor to donor variability in the Western blots from all 8
conditions, separate cell cultures were conducted with fewer treatments and instead of
fractionation we performed a WCL to extract all the proteins and reblotted for HDAC1.
Much to our surprise, HDAC1 was no longer decreased in Meth treated MDM compared
to control (Fig. 3.10.). In fact, no treatments reached significance for HDAC1 in WCL.
3.3.2. Consequences of decreased HDAC1 is changes in the histone acetylation
Decreases in HDAC1 would be expected to lead to increases in HDAC1-specific
acetylation sites. Some PTMs that have been reported to be specific to HDAC1 by ChIP
are histone 4 lysine 5 (H3K5), histone 3 lysine 18 (H3K18), and histone 3 lysine 9
(H3K9) [67, 68]. As expected with decreased HDAC1, we observed a large increase of
H3K18 and H4K5 due to Meth but not H3K9 (Fig. 3.11.).
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Gene
Treatment
Fold
Expression

HDAC1
METH*
CONTROL
1.0 ± 0.0

-8.0 ± 1.8

HDAC6

CONTROL

METHns

1.0 ± 0.0

1.7 ± 0.6

Table 3.1. Expression levels of HDAC1 and HDAC6. MDM were cultured with 100 µM
Meth or control (MSFM) for 48 hours. Total mRNA was extracted and PCR was
performed. Relative to control Meth caused a significant decrease of HDAC1 mRNA but
not HDAC6. Data are represented as the mean±SD fold expression of 3 independent
experiments. An asterisk (*) indicates p<0.05 by a Student’s t-test whereas, ‘ns’ is not
statistically significant. Fold changes are normalized to the housekeeping gene GAPDH.
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Figure 3.3. Timeline for treatments. Monocytes are differentiated in the presence of
MCSF for 7 days. On day 7, MDM are infected with HIV-1ADA. Three days post-infection,
MDM are exposed to 100 µM Meth and maintained for 48 h. On day 12 days post-plating
or 5 days post-infection MDM are treated with cART (ATV, FTC, and TDF) at 5 µM each
until day 17.
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Quantification of
total HDAC

Subcellular
quantification of
HDAC

Identification of
PTMs

Figure 3.4. Schematic of sample preparation. A diagram of how the macrophages will
be processed and the corresponding methods.
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Figure 3.5. Experimental conditions for elucidating the effects of HIV infection,
Meth abuse, and antiretroviral therapy on the transcriptional machinery in
macrophages. Macrophages will be infected, exposed to Meth and/or treated with cART
constituting a total of 8 experimental conditions to determine the individual and
compounded effects of each treatment on the macrophage proteome.
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Figure 3.6. Protein levels of HDACs in the cytosol. Description of treatments and
timeline refer to Figure 3.3. Proteins extracted from the cytosol of MDM and levels of
HDAC1-6 were quantified Densities of HDAC1 were normalized to actin using ImageJ
software. Data are represented as the mean±SE fold expression of 3 independent
experiments.
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Figure 3.7. Quantification of HDAC protein levels in the nuclear fraction.
Description of treatments and timeline refer to Figure 3.3. Densities of HDAC1 were
normalized to actin using ImageJ software. Data are represented as the mean±SE fold
expression of 3 independent experiments.
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*

Figure 3.8. Protein levels of HDAC1 from the cytosol and nucleus in control and
Meth treated human macrophages. Plot re-represents the samples juxtaposed for
HDAC1 from the levels in the cytosol and nucleus (Fig. 3.5. & 3.6). MDM were either
mock treated (control media) or with 100 µM Meth for 48 h and then maintained for 5
days with no other treatments. MDM were fractionated and HDAC1 protein was detected
by Western blot. An asterisk (*) indicates p<0.05 by a Student’s t-test. Densities of
HDAC1 were normalized to actin using ImageJ software, n=3.
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ImageJ software. Single image capture at 63X oil immersion objective. An asterisk (*)
indicates p<0.05 by a Student’s t-test. Scale bar is 20 µm.

89

Figure 3.10. HDAC1 levels in WCL. In a separate experiment, MDM were either mock
treated (control media), exposed to 100 µM Meth, or infected with HIV-1. Keeping with a
similar timeline when there was 8 conditions, MDM were infected on day 7 and exposed
to Meth on day 10, then maintained for 48 hours before being lysed and proteins
extracted. Quantitative Western blot analysis of HDAC1 from 5 µg of each sample. of
HDAC1 were normalized to actin using ImageJ software, n=4.

90

Figure 3.11. Western blot analysis of acetylation of H4K5 and H3K18. Two known
targets for HDAC1 are H4K5 and H3K18 and changes in HDAC1 will effect acetylation at
these sites. Control and Meth MDM treatment was described in Cell Culture and Sample
Preparation (section 4.2.1). Five µg of histones from each sample were loaded and
incubated at 1:1000.
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3.4.

Discussion
In this study, we found that Meth decreases HDAC1 at the protein level. This was

explained by the corresponding decrease in mRNA levels. A decrease in HDAC2-6
protein levels or a decrease in HDAC6 mRNA would have been an indicator that Meth
exacerbates the degradation pathway or inhibits translation, respectively. Our conclusion
from not detecting HDAC5 and 6 by Western blot is that the antibodies were not specific
enough considering HDAC6 was quantified using the more sensitive technique, RTqPCR. In addition, the low number of cell cultures or high variability of HDAC levels
among healthy donors might have contributed to HDAC2-4 being inconclusive.
Therefore, more studies need to be done with more donors to verify that Meth, HIV-1
infection, and/or cART do not have an effect on HDAC2-6 levels. The confocal images,
relative quantification of HDAC1 by RT-PCR and the correlation between the increases
in acetylation and HDAC1, allowed us to conclude that Meth induces a decrease in both
the protein and RNA level. This is analogous to other reports on Meth addict brains
suggesting a similar mechanism in macrophages [61, 62].
The rationale that HDACs result in gene silencing is twofold: one, because of the
biochemistry between the histone tails and DNA and two, because of in vitro data. Nonacetylated (or deacetylated by HDACs) lysine residues on the N-terminal histone tails
are positively charged and electrostatically attracted to the negatively charged
phosphate backbone of DNA. This interaction between DNA and histones tails keep
chromatin in a closed formation and inaccessible for transcription. Another reason HDAC
is associated with gene repression is treatment with HDACi resulted in the abrogation of
gene repression [69, 70]. However more recently, it has been found that HDAC1 is
present at many transcriptionally active genes [71]. Therefore, whether the downstream
effect of the Meth-induced decrease of HDAC1 is gene silencing or activating still needs
to be explored.
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The rapid decreases of HDAC1 within 24 h of Meth exposure was expected
because Meth increases cytokine production and HDAC1 suppresses the NF-κBdependent genes like TNF-α, IFN-β and other cytokines in macrophages and T-cells [7277]. However, it was surprising to see no changes in HDAC1 in the HIV or HIV/Meth
samples and especially, HIV/Meth not having an additive effect on HDAC1. Literature
would suggest that HIV dysregulates HDAC1 to allow for the expression of viral genes
and our macrophages are actively producing HIV (p24 ELISA not shown). One
explanation is, again, that the number of cell cultures was not robust enough to
demonstrate statistical significance as there is a trend of decreased HDAC1 in the
cytosol, nucleus, and whole cell lysates in Meth and HIV/Meth MDM compared to
control.
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Chapter 4

Method Development: Pressure Assisted Digestion of
Proteins Using a Barocycler
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4.1.

Introduction
Sample preparation for high-throughput analyses of proteins is at the center of

proteomic profiling experiments [1-4]. The multi-step nature of proteomic studies makes
reproducibility, standardization, and normalization key to reducing analytical variability.
Other than intact protein analysis and the rarely used chemical methods for protein
digestion, the majority of proteomic experiments contain a step involving the enzymatic
digestion of proteins for mass spectrometry (MS)1-based protein identification and
quantitation. It is important to note that each type of proteolytic digestion can yield a
different number and type of peptides, thereby limiting the scope of information related to
the structure and function of the protein of interest [4]. Therefore, the concept of a
universal sample preparation method has several limitations, thereby driving
technological and methodological development to create new avenues for enhancing
sample preparation.
Conventional enzymatic digestion protocols typically employ an overnight
reaction to ensure complete digestion of peptides. Still, samples can contain cleavage
sites that are missed during digestion. Namely, a reduced rate of specific peptide bond
hydrolysis and/or the presence of posttranslational modifications (PTMs) contribute to
this effect [5]. Several techniques, such as high-intensity focused ultrasound (HIFU),
microwave radiation, and performing the digestion under conditions of high pressure,
have been developed and modified to overcome these digestion shortcomings and to
decrease the time needed for complete digestion of the protein [6-11]. The technique
involving high-pressure conditions applies pressure up to 40 kpsi and appears to provide
improved results as compared with HIFU and microwave radiation. HIFU is based on
precise modulation of ultrasound, which was a significant problem in the past; however,
current ultrasound techniques have found application (e.g., electrical impedance
tomography, optical tomography) [12]. On the other hand, reactions controlled by
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microwave radiation are so rapid that the generated reaction heat can lead to by-product
formation and, in some cases, to degradation. The limitations of HIFU and microwave
radiation have prompted us to test whether pressure cycling technology (PCT) can be
used sufficiently for accelerated enzymatic digestion and be applicable in proteomics.
The use of PCT for enhancing enzyme activity was introduced during the early
1990s. However, the development of new instrumentation resulted in more user-friendly
methods, leading to development of new applications [13, 14]. Here, we evaluate the
Barocycler NEP 2320 (Pressure Biosciences, South Easton, MA, USA) as a platform for
analyzing the enzymatic digestion of proteins under high pressure. The Barocycler NEP
2320 applies PCT to accelerate enzymatic digestion of samples, which in turn are used
for analytical purposes. In the current study, histone H4 is used as the model protein.
Histones, in addition to their functions in epigenetic regulation, represent a class of
proteins that can carry multiple homo and heterogeneous PTMs, thereby altering
susceptibility for enzymatic digestion, which subsequently causes additional difficulties in
profiling studies. Using PCT, we were able to reduce the time of enzymatic digestion of
histone H4 from 18 h to 120 min while maintaining 100% of sequence coverage
identified by tandem MS (MS/MS) after digestion under atmospheric pressure.

4.2.

Materials and Methods

4.2.1. Reagents
High-performance liquid chromatography (HPLC) gradient-grade acetonitrile
(ACN) and water were purchased from Fisher Scientific (Fair Lawn, NJ, USA).
Trifluoroacetic

acid

(TFA,

Reagent-Plus,

99%),

urea,

ammonium

bicarbonate

(ReagentPlus, 99%), iodoacetamide (IAA, Sigma Ultra), and α-cyano-4-hydroxycinnamic
acid (CHCA) were purchased from Sigma–Aldrich (St. Louis, MO, USA). Molecular-
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grade dithiothreitol (DTT) and sequencing-grade chymotrypsin were purchased from
Promega (Madison, WI, USA). Recombinant human histone H4 (P62805) was
purchased from New England Biolabs (Ipswich, MA, USA). Primary human monocytes,
obtained by elutriation from healthy donors, were used to isolate histone fractions using
a Qproteome Nuclear Protein Kit (Qiagen, Hilden, Germany) [15, 16]. The protein
fractions obtained using Qproteome were quantitated using a Pierce 660-nm protein
assay and prediluted protein standards (bovine serum albumin, Thermo Scientific,
Rockford, IL, USA).
4.2.2. Histone fractionation
The histones were isolated from the primary human monocytes using the Qproteome kit
from Qiagen. The isolated histones were further fractionated using a reversed phase
HPLC (RP–HPLC) system (Shimadzu Scientific Instruments, Columbia, MD, USA),
which was equipped with an ultraviolet (UV) detector and Shimadzu LC Solution
software for data acquisition. Chromatographic separations of 100 μg of proteins per
injection were performed using an analytical HPLC C4 column (250 × 4.6 mm, dp = 5
μm, 300 Å) from Advanced Chromatography Technologies (Aberdeen, Scotland). Mobile
phase A was 5% ACN in water plus 0.1% TFA, and mobile phase B was 90% ACN plus
0.1% TFA. Fractionation was initiated with 100% mobile phase A for 5 min. From 5 to 15
min, mobile phase B was ramped up to 35% and then held continuously for 10 min.
From 25 to 100 min, the amount of solvent B was increased to 65%, followed by ramping
up to 100% in 20 min. This condition was maintained for 5 min, and then the amount of
solvent B was decreased to 0% in 5 min and held for 145 min.
4.2.3. Enzymatic protein digestion
Proteolytic digestion under atmospheric conditions was performed for at least 18
h but no longer than 24 h. In this article, enzymatic digestion under atmospheric
pressure is referred to as the “conventional method.” In this study, we compared
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digestion assays of recombinant and native human histone H4 using the conventional
method compared with PCT using a Barocycler NEP 2320. After completing digestions
of recombinant protein, an AB SCIEX 4800 matrix-assisted laser desorption/ionization–
tandem time-of-flight (MALDI–TOF/TOF) mass spectrometer (Framingham, MA, USA)
was used to analyze resulting peptides. A nano liquid chromatography (nanoLC) LTQOrbitrap mass spectrometer was used to analyze peptides from digestions of native
histone H4 isolated from human monocytes.
4.2.4. Conventional method of proteolytic digestion
Dried human histone H4 was dissolved in 20 μl of 8 M urea and 0.4 M NH4HCO3,
and the pH was adjusted to between 7.5 and 8.5. Proteins were reduced by the addition
of 5 μl of 45 mM DTT and incubated for 15 min at 50 °C. After cooling to room
temperature, the sample was alkylated through the addition of 5 μl of 100 mMIAA and
incubated in the dark at room temperature for 15 min. Following alkylation, the digestion
buffer was diluted with water to a final concentration of 2 M urea and 0.1 M NH4HCO3.
Chymotrypsin was added to the sample in a ratio of 1:4 (w/w) enzyme to protein.
Digestion occurred at 37 °C for 18 h. Next, the reaction was quenched by acidifying the
sample through the addition of 50 μl of TFA.
4.2.5. PCT digestion
All steps of the tryptic digestion protocol preceding incubation (ambient or high
pressure) were identical for the Barocycler NEP 2320 and conventional methods.
However, after the sample was alkylated, in the case of using the Barocycler NEP 2320,
samples were transferred to PCT MicroTubes and placed in the metal holder component
of this instrument. After digestion, samples were acidified using 50 μl of TFA to quench
the reaction.
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4.2.6. Mass spectrometry
MALDI–TOF/TOF—In preparation for MS analysis, peptides resulting from PCT
digestion of recombinant human histone H4 (1 μg) were desalted using reversed phase
ZipTip pipette tips with 0.2 μl of C18 resin (Millipore, Billerica, MA, USA). For sample
analysis, an AB SCIEX 4800 MALDI–TOF/TOF mass spectrometer was used. First, 1 μl
of digested sample was spotted onto a MALDI plate and co-crystallized with 1 μl of
CHCA matrix (5 mg/ml in 50% ACN and 0.1% TFA). The droplets were dried in a
desiccator under decreased pressure. Spectra acquisition and data processing were
performed using 4000 series Explorer software version 3.5.1 (AB SCIEX); the software
settings were in a reflectron-positive mode at fixed laser intensity with a low-mass gate
and delayed extraction. Peptide masses were acquired for m/z values ranging from 800
to 2500 Da. MS spectra were summed from 1000 laser shots by an Nd-YAG laser
operating at 355 nm and 200 Hz. MS/MS spectra were acquired in 1 kV positive mode.
The 1000 shots were summed in increments of 50. Database searches were performed
on

the

SwissProt

database

(http://www.matrixscience.com).

The

using
search

Mascot
parameters

MS/MS
were

Ion
as

Search

follows:

(i)

carbamidomethylation on cysteine and oxidation on methionine were variable
modifications; three missed chymotrypsin cleavage sites were permitted; the mass
accuracy tolerance for the peptide (MS) was set at 15 ppm and for fragments (MS/MS)
was set at 0.5 Da.
ESI–LC–MS/MS—Histone H4 isolated and fractionated from human monocytes
was digested using both conventional and PCT methods. After digestion, and prior to
analysis, samples were desalted using reversed phase ZipTip pipette tips with 0.2 μl of
C18 resin as per the manufacturer’s protocol (Millipore). Next, samples were analyzed
using a high resolution mass spectrometry electrospray ionization (ESI)–LC–MS/MS
system in a nanospray configuration (LTQOrbitrap, Thermo Scientific, West Palm Beach,
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FL, USA) coupled with a nanoLC system (TEMPO nano MDLC System, AB SCIEX) and
using a microcapillary RP-C18 column (New Objectives, Wo-burn, MA, USA). The
database search was performed using Proteome Discoverer 1.2 software (Thermo
Scientific). The search parameters were as follows: (i) carbamidomethylation on cysteine
and oxidation on methionine were variable modifications; three missed chymotrypsin
cleavage sites were permitted; the mass accuracy tolerance for the peptide (MS) was
set

4.3.

at

15

ppm

and

for

fragments

(MS/MS)

was

set

at

0.5

Da.

Results

4.3.1. Pressure optimization
To optimize the pressure and time for the digestion for recombinant human
histone H4, we performed multiple digestions at different pressures and for different time
points (see Tables 4.1 and 4.2 below). Experiments were performed in triplicate. Based
on manufacturer recommendations, we selected the following three pressure settings:
10, 15, and 25 kpsi. Cycling consisted of 30 cycles at 1 min each; each cycle was run for
50 s at the pressure setting of interest, followed by 10 s of stabilization at atmospheric
pressure. The temperature was ambient, and chymotrypsin was used at a concentration
of 0.5 μg/μl. The resulting digest of the protein was analyzed using an AB SCIEX 4800
MALDI–TOF/TOF mass spectrometer for the recombinant histone H4. The digest of
recombinant histone H4 revealed seven peptides and constituted a nearly full sequence
except for the first amino acid and the C-terminal fragment, a 100GFGG103 (MW =
336.14) tetrapeptide. The peak list, created by 4000 series Explorer software, was used
in parallel to acquire MALDI–TOF/TOF data. This data consisted of (i) the m/z ratio
(including an average mass with lower and higher m/z recordings), the peak height
(peak intensity), the signal/noise ratio, (iv) resolution, and (v) the area under the peak.
The peak with highest intensity represents 100%. Considering that in each experiment
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the only variable parameter is the applied pressure, we theorized that peak intensity
would reflect the relative change in the amounts of each peptide generated by such
digestion, thereby more of any given peptide in the mixture. The m/z peak of such a
peptide is expected to have higher intensity. Therefore, we elected to demonstrate
pressure optimization based on the relative comparison of peak intensities for each
peptide generated using pressures of 10, 15, and 25 kpsi. Results for all peptides are
summarized in Table 4.1, and Fig. 4.1 is a bar graph comparing the changes in peak
intensity for the two N-terminally located peptides that are postulated to be of the
greatest biological importance. In all three samples (10, 15, and 25 kpsi), the peptide
90ALKRQGRTLY99 showed the highest intensity, thereby setting up 100%, which were
0.24 1.2, and 1.3 × 104, respectively. Based on these data, we postulated that we did
not reach the signal saturation for this mixture of peptides under our experimental
conditions, thereby allowing us to make relative comparisons. Comparisons should be
performed with caution and can be performed for only a single peptide at three digestion
conditions (horizontally, e.g., for one given peptide), assuming that the rate of ionization
remains constant and signal suppression from other peptides is negligible. Based on the
data presented, it was determined that a pressure of 10 kpsi was too low, as reflected by
the low signal intensity overall and for each of the seven peptides. When comparing
peak intensities for pressures of 15 and 25 kpsi, results indicate that 15 kpsi was
beneficial for the signal intensity of peptides 1, 2, and 5 (see Table 4.1), which were
further digested and/or degraded at 25 kpsi. If low-specificity chymotrypsin was used, we
would expect that the peptide 74TEHAKRKTVTAMDVVY89 would be further fragmented
into the following three peptides: 74TEH76, 77AKRKTV-TAM85, and 86DVVY89. This
fragmentation is expected to result in a drop in the peak intensity for this particular intact
peptide. For example, when low-specificity chymotrypsin is used, the peptide
2SGRGKGGKGLGKGGAKRHRKVL23 could be further fragmented at 25 kpsi into the
109

following three peptides: 2SGRGKGGKGL11, 12GKGGAKR18, and 19HRKVL23.
Because this was not observed, we conclude that susceptibility of peptide bonds cleaved
under PCT conditions is, to some extent, selective. This selective cleavage could be
advantageous if one investigates proteins with point mutations, splice variants, and/or
isoforms and when the aim of the experiment is not only to have maximal sequence
coverage but also to have overlapping sequences. For other peptides, a pressure of 25
kpsi appears to be optimal. It has been postulated that, from a biological point of view,
the most important part for all histones is the N-terminus end (also called the “histone
tail”) [17]. This end is arbitrarily set to be approximately 30% of sequence from the Nterminal end of histones; in histone H4, this would be the first 38 amino acids [18]. The
N-terminus portion of histone has been shown to play an important role in chromatin
remodeling and transcription regulation. In summary, we conclude that 15 kpsi is the
optimal pressure to digest histones for further studies.
4.3.2. Time optimization at 15 kpsi
Based on reasoning presented above with respect to fragmentation and pressure, we
attempted to optimize digestion time at a pressure of 15 kpsi. For this part of data
analysis and interpretation, we used the same criteria as we used for analysis applied to
pressure optimization as described in the previous section. Results for all peptides are
presented in Table 4.2, and Fig. 4.2 is a bar graph comparing the changes in peak
intensity for the two N-terminally located peptides that are postulated to be of the
greatest biological importance. For peptides 1, 2, 3, and 5, the optimal time appears to
be 120 min; when extended, this leads to a decrease in the signal intensity. The
decrease in the peak intensity for the peptides shown in Table 4.2 would again suggest
that a longer period of time pushes the digestion reaction to yield smaller peptides. In
summary, we optimized the conditions for chymotrypsin digestion of recombinant human
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histone H4 as 15 kpsi for 120 cycles. Each cycle was 1 min long and consisted of 50 s of
high pressure and 10 s of atmospheric pressure.
4.3.3

Summary of PCT using chymotrypsin

Fig. 4.3 shows a representative spectrum of MALDI–TOF/TOF spectrometric analysis of
fragments generated from chymotrypsin digestion of recombinant histone H4 using the
optimal conditions established by this study. Table 4.3 shows sequences of peptides,
which provide nearly complete sequence coverage. It is important to note that we were
able to sequence the entire N-terminal end (histone tail) of histone H4. We also
performed MS/MS analysis of five minor peaks with m/z 864.9, 1021.5, 1798.3, 2108.0,
and 2331.1, but we were unable to assign them to any part of the histone H4 sequence,
concluding that they are most likely part of contamination.
4.3.4. RP–HPLC fractionation of intact histones
After optimization of the PCT method using recombinant histone H4, we moved to the
next step involving intact histones isolated from biological material. The source of
histones used for this study was human monocytes obtained from elutriated blood of
healthy donors (see Materials and methods). For preparation, histones were subjected
to RP–HPLC fractionation (Fig. 4.4), followed by identification of collected fractions using
MS. Histones H2B, H4, H2A, and H3 were eluted as separate peaks between 50 and 70
min (Fig. 4.4 inset). Peaks appear to be broad, which is likely due to small differences in
the

elution

time for

post-translationally

modified

forms

rather

than

due

to

chromatographic conditions. Histone H1 was eluted prior to the 50-min time point;
however, it was not collected for the purpose of this study. A relatively broad fraction
containing histone H4 was collected, as shown in the box in the Fig. 4.4 inset, and used
for further experiments.

111

4.3.5. Chymotryptic digestion of native histone H4 using conventional and PCT
methods
Equal amounts of the HPLC fractions containing histone H4 were digested using
either optimized PCT or the conventional method (i.e., atmospheric pressure). Peptides
resulting from these digestions were analyzed using an LTQ-Orbitrap in a nanoLC–ESI–
MS/MS configuration. The reason we used MALDI–TOF/TOF for digested recombinant
histone H4 and used ESI–MS/MS for histone H4 purified from monocytes was because
we expected a higher complexity in histone H4 from monocytes compared with the
recombinant sample. Both digestion conditions yielded 75% sequence coverage (Fig.
4.5), with 2SGRGKGGKGLGKGGAKRHRKVL23 being the only missing peptide. This was
expected, to some extent, because the N-terminal tail of histone H4 is extensively posttranslationally modified. Such modifications can lead to a digestion that differs from nonmodified proteins.
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Table 4.1. Optimization of PCT pressure based on relative intensity of MALDITOF/TOF peptide peaks.
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Table 4.2. Optimization of PCT time based on relative intensity of MALDI-TOF/TOF
peptide peaks.
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Table 4.3. Peptides generated using conventional chymotrypsin digestion of
recombinant human histone H4.
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Figure 4.1. Pressure optimization for two peptides from the N-terminal tail portion
of recombinant human histone H4. Pressure setting was varied for 10, 15, or 25 kpsi
at a constant 30 min digestion.
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Figure 4.2. Time optimization for two peptides from the N-terminal tail portion of
recombinant human histone H4. The amount of time the Barocylcer digested was
either 30, 120, or 200 min at a constant15kpsi.
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Figure 4.3. MALDI–TOF mass spectrum of recombinant human histone H4
digested using the PCT method. The numbered peaks match those generated by
conventional chymotrypsin digestion, providing 95% sequence coverage, and are listed
in Table 4.3.
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Figure 4.4. RP–HPLC chromatogram showing fractionation of histones using UV
detector set at 214 nm. The inset shows an enlarged range of the peptides containing
peaks assigned to respective histones.
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Figure 4.5. Comparison of peptide identification using digestion on high pressure
and atmospheric (conventional) pressure. (A) conventional digestion; (B) histone H4
sequence (P62805 H4_HUMAN); (C) PCT digestion.
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4.4.

Discussion

4.4.

Discussion
The major advantage of the PCT method using the Barocycler NEP 2320 is that

it significantly reduces the time necessary to proteolytically digest proteins. For example,
using the PCT method, proteins can be digested in 120 min at 15 kpsi instead of 18 h at
atmospheric pressure. It is important to note that our experimental approach focused on
only one protein, and not additional proteins that are difficult for proteolytic digestion,
thereby limiting the scope of this study. For example, this technology may be beneficial
for tests involving highly glycosylated proteins such as mucins. Another limitation in our
study is that the only proteolytic enzyme tested was chymotrypsin. Additional proteolytic
enzymes are available and should be tested in the future.
One observation from this study was that PCT using a Barocycler NEP 2320
technology platform did not show a substantial qualitative difference between 10 and 15
kpsi, and if based on peak intensity, 15 kpsi provided a more intact protein to be
digested. However, there was a decrease in major peptides measured by peak intensity
under 25 kpsi, which may indicate that proteolytic digestion was further forced at this
pressure to yield smaller fragments. We find this phenomenon to be interesting for
further explorations because it may be very useful in studies where the in-depth analysis
of splice variants or isoforms is of interest. Overall, we conclude that PCT is a promising
technique for more controlled sample preparation, as compared with arbitrary overnight
incubation, and clearly reduces time for this step. However, additional efforts are needed
to refine the experimental protocols, and more formal studies need to be performed.

121

4.5.

References

1.

Singleton, C., Recent advances in bioanalytical sample preparation for LC-MS
analysis. Bioanalysis, 2012. 4(9): p. 1123-40.

2.

Finoulst, I., et al., Sample preparation techniques for the untargeted LC-MSbased discovery of peptides in complex biological matrices. J Biotechnol,. 2011:
p. 245291.

3.

Li, F., D. Fast, and S. Michael, Absolute quantitation of protein therapeutics in
biological matrices by enzymatic digestion and LC-MS. Bioanalysis, 2011. 3(21):
p. 2459-80.

4.

Biringer, R.G., et al., Enhanced sequence coverage of proteins in human
cerebrospinal fluid using multiple enzymatic digestion and linear ion trap LCMS/MS. Brief Funct Genomic Proteomic, 2006. 5(2): p. 144-53.

5.

Hamady, M., et al., Does protein structure influence trypsin miscleavage? Using
structural properties to predict the behavior of related proteins. IEEE Engineering
in Medicine and Biology Magazine, 2005: p. 58-66.

6.

Carrera, M., et al., Fast monitoring of species-specific peptide biomarkers using
high-intensity-focused-ultrasound-assisted tryptic digestion and selected MS/MS
ion monitoring. Anal Chem, 2011. 83(14): p. 5688-95.

7.

Carreira, R.J., et al., New findings for in-gel digestion accelerated by highintensity focused ultrasound for protein identification by matrix-assisted laser
desorption ionization time-of-flight mass spectrometry. J Chromatogr A, 2007.
1153(1-2): p. 291-9.

8.

Lill, J.R. and V.J. Nesatyy, Microwave-assisted protein staining, destaining, and
in-gel/in-solution digestion of proteins. Methods Mol Biol, 2012. 869: p. 521-32.

122

9.

Osula, O., S. Swatkoski, and R.J. Cotter, Identification of protein SUMOylation
sites by mass spectrometry using combined microwave-assisted aspartic acid
cleavage and tryptic digestion. J Mass Spectrom, 2012. 47(5): p. 644-54.

10.

Marshall, P.L., et al., Pressure cycling technology (PCT) reduces effects of
inhibitors of the PCR. Int J Legal Med, 2013. 127(2): p. 321-33.

11.

Powell, B.S., et al., Pressure cycling technology in systems biology. Methods Mol
Biol, 2012. 881: p. 27-62.

12.

Bal, G., Cauchy problem for ultrasound modulated EIT. arXiv, 2012. 1.

13.

Lee, B., et al., Rapid and efficient protein digestion using trypsin-coated magnetic
nanoparticles under pressure cycles. Proteomics, 2011. 11(2): p. 309-18.

14.

Gross, V., et al., Tissue fractionation by hydrostatic pressure cycling technology:
the unified sample preparation technique for systems biology studies. Journal of
Biomolecular Techniques, 2008. 19: p. 189-99.

15.

Gendelman, H.E., et al., Efficient isolation and propagation of human
immunodeficiency virus on recombinant colony-stimulating factor 1-treated
monocytes. Journal of Experimental Medicine, 1988. 167: p. 1428-41.

16.

Go, E.P., et al., Glycosylation site-specific analysis of clade C HIV-1 envelope
proteins. J Proteome Res, 2009. 8(9): p. 4231-42.

17.

Hou, H. and H. Yu, Structural insights into histone lysine demethylation. Curr
Opin Struct Biol, 2010. 20(6): p. 739-48.

18.

Zheng, C. and J.J. Hayes, Structures and interactions of the core histone tail
domains. Biopolymers, 2002. 68: p. 539-46.

123

Chapter 5

Summary and Conclusions

124

5.1.

Summary and Conclusions
We looked directly at the effects of Meth on a macrophage function, cytokine

production, in macrophages and a possible mechanism for the observed effects. Our
study was the first exploratory and most comprehensive study for measuring the levels
of cytokines in Meth exposed macrophages over time and as a result, determined that
Meth increases the production of more pro-inflammatory cytokines than antiinflammatory cytokines in the first few hours of administration. Cytokines play a large
role in chemoattraction, proliferation, programmed cell death, cell phenotype switching,
and regulation of inflammation. Further studies are needed to determine which of the
cytokines expressed are secreted and the function they will have on surrounding target
cells. However, it is clear that the dysregulation caused by Meth in the cytokines
expressed in our study can have complex and numerous effects on other cell types and
tissue. Another finding was that the cytokine changes are dynamic meaning they change
based on concentration of Meth and time of exposure. One cytokine, in particular was
strongly down-regulated, CCL7. The significance is CCL7 is it is critical for the clearance
of cryptococcal neoformans, a fungal infection common in HIV-1 patients and Meth use
exacerbates the pathogenesis. First, we investigated whether the silencing of CCL7 was
due to DNA methylation but there was not a large enough increase that would yield gene
repression. Therefore, we looked at which mechanisms induce CCL7 and found it is
expressed by activation of TLR9 and accordingly, we explored the signaling pathway
and the mediators that Meth might be altering to shift the expression. We measured by
different means the levels of TLR9, IRAK, the activated state of IRAK, degradation of the
inhibitory protein of NF-κB, IκB, and transcription factors such as STAT1, NF-κB, IRF7
and phospho-IRF7. None of these factors seemed to change due to Meth exposure, at
least not at the times we measured and under the conditions we measured. Additional
and more thorough work needs to be done on how the signaling factors that mediate
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TLR9 signaling change due to Meth. But in conclusion Meth affects cytokine production
in macrophages and is mediated, at least in part, by TLR9 signaling.
In the other study, we looked at HDAC1-6 and found that HDAC1 was
significantly decreased in Meth exposed macrophages. There was a trend of decreased
HDAC1 in HIV and HIV/Meth macrophages. The next step is to determine the effects of
decreased HDAC1 on the functions of macrophages. Predictably, expression of viral
loads would increase since HDAC1 is allows HIV to remain in a latent state [1].
Interestingly though, decreased HDAC1 in has been implicated in Meth-induced
alterations of gene expression in the nucleus accumbens, a brain region responsible for
feeling pleasure and reward, exacerbating addiction to Meth [2] These results suggest
that the alterations in gene expression by HDAC1 can simultaneously worsen addiction
and HIV infection.

5.2.

Challenges and Future Directions
For our study we detected and measured levels of HDAC1 by three methods:

densiometric quantification of immunoblots, qRT-PCR and confocal imaging. The
biggest challenge came from quantitative Western blots of HDAC1. Despite including
multiple donors, resulted in inconclusive data due to the large standard deviation
preventing the statistical significance of the data. Although quantitative Western blots are
common in the field, they are done improperly, regularly. Variability of densiometric
analysis can be from differences in the most upstream step of processing cell cultures or
lack of complete lysis of cells. Next, improper quantitation can result in differences due
to the type of protein concentration method used for example: Pierce 660 versus
Bradford versus absorbance at 280 nm, since each method exploits different properties
of proteins. In conjunction with the protein concentration issue, is the oversaturation of a
loading control like actin. Actin is so abundant in cells that it can easily reach the
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detection limits of X-ray films and imaging softwares if loading more than 3 µg of cell
lysate whereas, that amount is sometimes not enough to detect the protein of interest
[3]. Other common loading controls like GAPDH are often used without first verifying that
there is no effect on the expression with different treatments. Use of positive controls for
Western blotting could significantly improve the quantitation for the protein of interest
and a good positive control is a lysate that over expresses the gene interest. Incomplete
separation of samples using SDS–PAGE usually comes from interfering reagents in the
lysis buffer. To this end, there are commercial kits that remove the restricting chemical(s)
but will most definitely cause a loss of proteins when purifying the sample. Thus, if
blotting for more than one protein of interest with similar molecular weights one must
decide if this cleaning up step is essential or overcome it by running two membranes, but
both options result in loss or use of additional sample. Next, incomplete transfer of
proteins to the PVDF membrane can occur to contribute to variations of densiometric
analyses but the loss can easily be determined by staining the gel with Coomassie
Brillant Blue. However, even if the step is not 100% efficient, Western blot is most likely
not sensitive enough to detect the small difference in incomplete transfer of proteins.
After transfer, membranes will be ready for primary antibodies but not all antibodies are
not created equal thus giving rise to less than specific detection of the protein of interest
and false positives or difficult time quantifying [4]. Running serial dilutions of the antibody
control with different amounts of the positive control cell lysate can help you assess the
quality of the antibody and can also prevent the oversaturation of the signal thus solving
two problems at once. The issues mentioned were not known or foreseen when
conducting the experiments and have taught me a lot.
In conclusion, Western blots should be used only for the detection of proteins in a
sample or used in a semi-quantitative manner meaning the only conclusion is less or
more due to a treatment. The alternative and always better approach to Western blot is
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an enzyme-linked immunosorbent assay (ELISA) for detection and quantification of
proteins and with recent advanced can be multiplexed with decreased variability, higher
reproducibility (intra-variability versus inter-variability), and increased confidence (or
decrease in false positives). However, the price of ELISA is positively correlated to the
number of proteins desired to be quantified. Future work should therefore always utilize
ELISA for protein quantification when available, otherwise implement a positive control
between donors, preferably more than three donors or replicates and a lysate of
commercial grade so that quality control has been performed and reproducibility is
similar between lots. Also, running a separate blot with far less protein loaded for actin
normalization simultaneously with samples so variability due to the electrophoresis
apparatus is minimized including separation of proteins and protein transfer to
membranes. Finally, the antibody quality and optimized concentration should be
determined before being used on the membranes by doing serial dilutions with the
positive control samples. This ensures linearity of signal and prevention of signal
saturation.
Another challenge encountered with the conclusion of the Meth-induced upregulation of acetylation on H3 lysine 18 and H4 lysine 5 is related to quantitative
Westerns since there was no normalization of PTMs to the total protein. Therefore, all
histone blots should have been normalized to the corresponding unmodified histone
otherwise, it is unknown whether Meth-induced an up-regulation of total histone or just
the PTM.
Future directions should incorporate the use of chromatin immunoprecipitation
with qPCR for both HDAC1 and specific histone acetylation sites to determine the genes
affected by the absence of HDAC1 in Meth exposed macrophages and crossed
referenced to the genes associated with the increase of acetylation due to Meth. This will
identify genes linked to HDAC1 but more importantly, can use bioinformatics on the data
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to understand how the genes correlate to function(s) of the macrophage that make it
more susceptible to infections, which is the ultimate goal of the study. Further
investigation needs to go into the trend of decreased HDAC1 in the HIV and HIV/Meth
treatments that never reached statistical significance in our experiments but are
confident from literature and our preliminary results that HDAC1 is involved in HIV
transcription and altered due to Meth.

129

5.3.

References

1.

Keedy, K.S., et al., A limited group of class I histone deacetylases acts to repress
human immunodeficiency virus type 1 expression. J Virol, 2009. 83(10): p. 474956.

2.

Martin, T.A., et al., Methamphetamine causes differential alteration in gene
expression and patterns of histone acetylation/hypoacetylation in the rat nucleus
accumbens. PLoS One, 2012. 7(3): p. e34236.

3.

Hammond, M., et al., A method for greater reliability in Western blot loading
controls: stain-free total protein quantitation, BioRad, Editor.

4.

Haverland, N., et al., Immunoreactivity of anti-gelsolin antibodies: implications for
biomarker validation. J Transl Med, 2010. 8: p. 137.

130

APPENDIX

131

132

133

134

